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Parkinson’s disease (PD) was first described by James Parkinson in 1817 in the 
monograph entitled ‘An Essay on the Shaking Palsy’. PD is the most common 
neurodegenerative movement disorder, and the second most common 
neurodegenerative disease after Alzheimer’s disease (AD), with more than 1% of 
people over 65 year old affected1. PD is clinically defined by adult-onset, progressive 
parkinsonism (the combination of akinesia, resting tremor, and muscular rigidity), 
and displays a beneficial response to dopamine-replacement therapy. This clinical 
syndrome correlates with neuronal loss and gliosis in the substantia nigra pars 
compacta and other brain areas, and in most patients with the formation of 
cytoplasmic inclusions called Lewy bodies (LB) and Lewy neurites in the surviving 
neurons2, 3. 
Enormous steps have been taken over the past two decades in understanding the 
neurobiology of PD, but the exact etiology of this devastating disease is still largely 
unknown.  
Currently, several mechanisms are believed to be implicated in the selective 
degeneration of dopaminergic neurons in PD. Although a common, unifying pathway 
at the cellular level has not been identified, the culprits might include the formation of 
protein aggregates and dysfunction of the proteasomal and lysosomal system, 
oxidative stress leading to mitochondrial dysfunction and apoptosis2, 3. 
 
The Mendelian forms of PD  
 
Until the end of last century hereditary influences in PD were thought to play a minor 
role. This led the scientific community to emphasize the role of environmental factors 
in the etiology of the disease. Certainly, ageing plays also an important role, as the 
incidence of PD increases dramatically with age. Epidemiological studies reveal that 
10–15% of PD has a positive familial history for the disease while the majority of 
cases are sporadic. Through linkage analysis and positional cloning approaches five 
genes have been definitely implicated in the etiology of PD. Mutations in the α-
synuclein4, 5 and leucine-rich repeat kinase 2 (LRRK2)6, 7 gene cause autosomal 
dominant forms whereas mutations in the parkin8, DJ-19 and PINK110 gene cause 
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autosomal recessive forms of PD. Furthermore, mutations in the PARK9/ATP13A211, 
PARK14/PLA2G612, and PARK15/FBXO713, 14, have been reported as rare causes of 
early onset parkinsonism with atypical clinical features which might be 
mechanistically distinct from classical PD. Finally, mutations in the genes for the 
nuclear receptor 4A2 (NR4A2, Nurr-1)15, ubiquitin C-terminal hydrolase L1 (UCH-
L1)16, Omi/HtrA217 and GRB10 interacting GYF protein 2 (GIGYF2)18 gene have 
also been described in PD cases, but their role in the disease remeins uncertain. 
Another three PD loci have also been mapped (PARK3, PARK10, PARK12)19-21, but 
the defective genes remain unknown.  
In addition to the Mendelian forms of PD, genetic risk factors for the disease have 
been investigated in several candidate genes and, more recently, in genome wide 
association studies22-25. With the exceptions of α-synuclein and microtubule 
associated protein tau (MAPT)26-31, none of the loci reported has so far been 
convincingly replicated in independent studies. Another exception is represented by 
the the gene involved in a  recessive neurometabolic disease, the glucocerebrosidase 
gene (GBA). Mutations in the GBA gene have a conspicuously high prevalence of PD. 
Screening of PD patients for GBA mutations then found a higher number of 
heterozygous mutations carriers as compared to healthy controls. Mutations have 
been found in about 2 to 4% of Caucasian PD patients, and less than 1% of controls.   
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Table 1 
___________________________________________________________________________________ 
 
Locus   Gene   Chromosome  Inheritance Clinical Presentation 
 
PARK1-4 α-Synuclein  4q21   AD   PD, Lewy body dementia 
PARK2  parkin   6q25.2-27  AR   Early onset PD 
PARK3  Unknown  2p13   AD   Typical PD 
PARK5  UCH-L1  (?) 4p14   AD   Typical PD  
PARK6  PINK1   1p36   AR   Early-onset PD 
PARK7  DJ-1   1p36   AR   Early-onset PD 
PARK8  LRRK2   12q12   AD   Typical PD 
PARK9  ATP13A2  1p36   AR   Early-onset parkinsonian-pyramidal syndrome with dementia 
PARK10  Unknown  1p32   Unknown Typical PD 
PARK11  GIGYF2 (?) 2q36-37   AD   Typical PD 
PARK12  Unknown  Xq21-q25  Unknown  Typical PD 
PARK13  Omi/HTRA2 (?) 2p12   Unknown  Typical PD 
PARK14 PLA2G6 (?) 22q  AR  Adult-onset dystonia-parkinsonism 
PARK15 FBXO7  22q  AR  Early-onset parkinsonian-pyramidal syndrome 
    (?) GBA  1q21  Unknown Typical PD 
___________________________________________________________________________________ 
Table 1. Known loci and genes for PD 
 
The LRRK2 gene – mapping and cloning 
 
Although the discovery of mutations in the α-synuclein, parkin, PINK1 and DJ-1 
genes clearly contributed to our understanding of the pathogenesis of PD, they were 
identified in a limited number of PD cases, often with early-onset or pathologically 
atypical features. 
In contrast, mutations in the LRRK2 gene turned out to be a frequent determinant of 
typical PD, in both early and late onset forms of the disease. Moreover the 
identification for the first time of LRRK2 mutations in sporadic cases has dramatically 
changed the previous opinion on the contribution of genetic factors in the 
development of PD in general. 
Introduction 
 14 
A new locus for PD, termed PARK8, was identified in a large family with autosomal 
dominant PD, known as the “Sagamihara family” from the region in Japan where the 
family originated from32. The clinical features in affected individuals of the kindred 
were reported to resemble very closely classical PD, with an average of symptoms 
onset at 51± 6 years. Initially, a pattern of “pure nigral degeneration” without Lewy 
bodies was found at autopsy in four PD patients examined, while another carrier of 
the disease haplotype developed pathologically-confirmed nigral degeneration, an 
atypical form of parkinsonism which is known to be associated with a synuclein-
positive brain pathology. However, a pathological follow-up study on this kindred 
revealed two additional cases with pure nigral degeneration and one with classical LB 
pathology33. In this family a genome wide linkage scan yielded significant evidence 
for linkage of PD to the centromeric region of chromosome 12 (12p11.2-q13.1). The 
haplotype analysis suggested an incomplete penetrance of the mutation32, 33. Linkage 
to the same region was found in a genome scan for Alzheimer disease, the locus 
being termed AD5, but this was mostly supported by the subset of families containing 
at least one affected individual with LB pathology34. In 2004 the linkage to PARK8 
was confirmed in two Caucasian families, “family A” (a German–Canadian kindred) 
and “family D” (from Western Nebraska) with dominantly inherited 
neurodegeneration35, and thereafter in several Basque PD36 families suggesting 
PARK8 to be a relatively common locus and refining the critical region. A wide 
clinical-pathological spectrum was shown in these families, including typical PD but 
also dementia and amyotrophy, diffuse Lewy body and tau pathology, nigral 
degeneration without inclusions and atypical, ubiquitin-positive inclusions37. 
In 2004 two independent groups, by positional cloning, identified mutations in a gene 
at that time annotated as DKFZp434H2111, which cosegregated with PD in several 
PARK8-linked pedigrees6, 7. The gene was renamed LRRK2 (leucine-rich repeat 
kinase 2) and the encoded protein LRRK2 or Dardarin (from the Basque term 
dardara, meaning tremor, since resting tremor was a consistent clinical feature of the 
Basque patients who carried LRRK2 mutations). The protein has an unknown 
function and the pathogenic mutations replace highly conserved residues among 
LRRK2 orthologues.  
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Subsequently, early in 2005, different groups identified a single LRRK2 mutation 
(c.G6055A) leading to a G2019S substitution in the encoded protein, which was 
present in familial and sporadic PD with unprecedented high frequency38-41. The 
following years have seen an explosion of research into the LRRK2 gene in PD and 
related disorders.  
Due to the large size of the open reading frame (more than 7.5 kb across 51 exons), 
most of the published studies only screened for the a very few recurrent mutations, 
especially those reported in the cloning papers (R1441C, R1441G, Y1699C and 
I2020T) and the common G2019S, which are so far considered as definitely 
pathogenic on the basis of clear cosegregation with disease in families and absence in 
ethnically matched healthy controls. The I2020T mutation was detected as well as the 
cause of disease in the original “Sagamihara family”42. 
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The G2019S mutation 
 
Prevalence of G2019S across populations 
 
G2019S is particularly important among the PD-causing mutations in LRRK2. This 
mutation was identified by several groups as a common cause of the disease, being 
detected initially in ~5–6% of large cohorts of familial PD in Europe and US38, 40, and 
in ~1–2% of sporadic PD from UK39. Due to the unprecedented high frequency in 
familial and late-onset classical parkinsonism, which in the past would have been 
identified as “idiopathic PD”, this specific mutation has been extensively studied 
worldwide. However, reviewing the literature on this specific mutation is difficult. 
The results from the different studies are often not directly comparable because of 
large differences in sample size. If the ethnic background of the population studied is 
not mentioned, especially in countries with highly mixed populations like U.S. and 
Brazil, the frequency of the mutation could be not representative of a given ethnic 
group. Moreover, the different definitions of ‘‘familial’’ versus ‘‘sporadic’’ disease 
can lead to an over representation of the mutation among (pseudo)sporadic cases who 
do have distant relatives with PD but lack affected first-degrees family members. 
Taking all these concepts into account, so far large screenings revealed that the 
frequency of G2019S is population specific.  
The G2019S mutation has been reported at the highest frequency (up to 37%) among 
familial PD cases of Arab descent and in 23% of familial Ashkenazi Jewish patients43, 
44
. Similar frequencies were replicated in independent studies on PD cases from 
Tunisia45-47 and in Ashkenazi Jews47-50. Remarkably, the frequency of this mutation 
was considerably high among sporadic cases (41% Arabs and 13% Ashkenazi Jews), 
and also rarely identified in healthy controls (3% Arabs and 1.3% Ashkenazi Jews). 
Other studies reported the presence of the G2019S among 1-2% of healthy North 
Africans, Ashkenazi and Sephardic Jewish subjects48, 49, 51, 52. Little is known about 
the prevalence in specific Middle Eastern, North African, and sub Saharan 
populations. A study suggests that the G2019S might be frequent in Turkey, having 
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been found in 1/26 (3.8%) of sporadic PD cases53, although this needs to be 
confirmed in a larger cohort. The mutation has not been identified so far in sub 
Saharan Africans (50 PD and 51 healthy Nigerian)54 , Yemenite Jews 50 and in Iran 
(205 PD)55.  
In Western Europe there is a South-North gradient of frequency. The G2019S is 
found in  9-16% of familial and 3-4% of sporadic PD patients in Portugal56, 57; it 
accounts for 6-16% of familial and 2-6% of sporadic PD in different region of Spain: 
Catalunia58, Cantabria59, 60, Asturias61, Galicia59 and Basque regions (patients without 
Basque ancestry)62; while it is less common in patients of Basque origin (1-2%)62. 
In Italy the G2019S mutation has been reported in 6-7% of familial and ~1-2% of 
sporadic cases38, 63-67. Similarly, in France the mutation accounts for ~3.5% of 
familial and ~1.9% of sporadic cases43, 68-71. Two independent screening in 
Sardinians, an isolated population, reported a frequency of ~1.5% in both familial and 
sporadic cases72, 73. Interestingly, the mutation that appeared to be common in the 
western Mediterranean basin is instead very rare in Greece and Crete74-77.  
A slightly lower frequency was reported in U.K. screenings of PD patients of 
Caucasian ethnicity (2.5% familial and 0.3-1.6% sporadic)39, 78, 79; and also in 
populations of Celtic and Baltic origin (Ireland 1.1% of familial PD41, 80; Norway 
~1.5% of familial PD81 and Sweden 1.4% of sporadic cases82). Mutation analyses in 
more than 300 familial and 1200 sporadic PD in Germany suggested a very low 
frequency of this mutation (0.8% of familial cases,83, 84 0.2-0.9% of sporadic)83-85, as 
well as in Belgium86, The Netherlands87 and Austria88; however, an independent 
study reported a higher frequency (6.4%) in familial PD from Germany, although the 
small sample size (30 families) limits the value of this finding89.  
Except from Poland and Serbia, where the G2019S appeared to be rare83, 90, 
frequency data in Eastern Europe are still lacking. On the contrary four studies have 
been performed in Russia, where the mutation accounts for 4-7% of familial and 1% 
of sporadic cases91-94. However, subjects were included from a mixed ethnic 
background, since at least two PD families and one sporadic case reported their ethnic 
origin as Ashkenazi Jews93. 
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An analogous observation can be done when analyzing patients from the U.S., where 
the frequency of the G2019S in Caucasian PD reaches 2-3.5% in familial and 0.5-
1.6% in sporadic cases45, 48, 95-101, it seems to be rare among American Indians and 
Afro-Americans (but the sample size for these two ethnic groups is still insufficient to 
make firm conclusions) 100, 101, whereas it was reported to be higher when patients of 
Ashkenazi Jewish ancestry were included48. In Canadian PD patients the G2019S is 
rare/absent102, 103. 
Four different populations of South America, where the Spanish, Portuguese and 
Italian ethnic backgrounds are strong, have been studied for this mutation. In 
Uruguay104 and Chile105 G2019S accounts for 3.5% of familial and 2,9-4.2% of 
sporadic cases. Controversial results came from large screening in Brazil (from 3 to 
6.8% in familial and 0 to 1.7% in sporadic cases), probably due to the high degree of 
ethnic heterogeneity within the study cohorts106-108. 
G2019S is rare/absent among Chinese patients with familial and sporadic PD109-112, as 
well as in Korea113, 114 and in India 112, 115. So far, only three patients have been 
reported with this mutation in Japan (0.7% of sporadic cases)47, 116. 
Finally, the mutation is present in Australia, among PD patients with European 
ancestry (2-6% of familial, 0.4% of sporadic PD)117, 118, while it has not been 
identified in Australian Aboriginal. 
 
Taken together, these data show that a single LRRK2 mutation represents the most 
frequent known genetic determinant of PD. The frequency of the G2019S mutation 
varies widely across populations, indicating that ethnicity is an important factor. For 
some populations, independent studies on the prevalence of the mutation are already 
available and often, the reported results are consistent. This should influence and 
speed the diagnostic genetic testing, especially in those countries where the 
prevalence of the mutation among PD is considerably high (20-40% of patients in 
North Africa and in Ashkenazi Jews). Nevertheless in most European countries and in 
U.S. at least 1% of sporadic and 2-6% of familial PD carry this mutation. These 
observations imply that most neurologists who treat patients with movement 
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disorders will see patients with LRRK2-related PD. This estimation could be even 
higher if we include the other LRRK2 definitely pathogenic mutations. 
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Figure 1 
Worldwide distribution of the G2019S mutation. 
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Origins of the G2019S mutation 
 
So far three different haplotypes have been identified in patients carrying the G2019S 
mutation. 
Haplotype 1 
The first studies on unrelated carriers of the G2019S of European (Italy, Norway, Poland, 
Ireland) or Middle Eastern–North African origin revealed that all shared the same 
haplotype, consistent with a common founder41, 43, 44, 66, 119, 120. Initially, the centromeric 
border of this haplotype was defined at the marker D12S2515, which led to a minimum 
~60 kb shared region41, 121. Using a likelihood based haplotype approach the mutation has 
been estimated to have arisen 725 years ago121. However, we found that a sample of 
G2019S-related haplotypes (mostly Italians) contained a very rare (0.1% in controls) allele 
at marker rs28903073, located upstream from D12S2515, which was in strong linkage 
disequilibrium with G2019S66. This suggested that the allelic differences observed among 
G2019S haplotypes at D12S2515 were likely due to recurrent mutation in an unstable 
microsatellite rather than recombination. Excluding the D15S2515 marker, the minimum 
shared region appeared larger, spanning ~160 kb which includes the promoter and most of 
the LRRK2 gene. The identification of a larger (at least at the 5’ end) shared haplotype 
suggests that variation at the promoter or other cis-acting regulatory elements are not 
important determinants of the phenotypic variation observed among G2019S carriers.  
Subsequently, the same haplotype has been identified among subjects carrying the G2019S  
mutation from Italy (independent subset)67, French46, Germany83, Russia91 Sardinia72, 73, 
Spain61, Portugal57, 66, Brazil66, Chile,105 Uruguay and Peru104, and Australia117.   
According to a general rule in population genetics, the geographic center of the origin of a 
mutation corresponds to the area where the same mutation is most frequent122. The highest 
prevalence of the G2019S mutation has been reported in Berbers51, followed by North 
African Arabs, Ashkenazi and Sephardic Jews. The frequency data combined with the 
identification of a common haplotype among these populations support the hypothesis that 
the mutation originated in North Africa or in the Middle East and than spread to other 
countries following the patterns of migration. 
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Three further studies provided important insights on the estimated age of the common 
founder for the haplotype 1 carriers. Analyzing the haplotypes of European and Ashkenazi 
Jews 120, and Tunisian G2019S carriers123, the age estimated of the common ancestor (using 
the 30-year intergeneration interval) was 2250 (95% CI 1650-3120) and 3120 (95% CI 
2340-4620) years ago, respectively (the results form the two dataset do not differ 
significantly since the 95% CI overlap). A third study, on Ashkenazi Jews only, estimated a 
more recent founder approximately 1525-1830 years ago (150-450 A.D)124. The latter 
estimation would fit with the absence of the G2019S in Yemenite Jews 50. The Yemenite 
Jews evolved completely separate from all of the other Jewish populations. Most of them 
arrived in Yemen in the early second century A.D. (~160 A.D.). Instead the Ashkenazi 
Jews migrated through Italy and southern Germany (Ashkenazi means ‘‘German’’ in 
medieval Hebrew) in the seventh/eighth century A.D., and spread from there to northern, 
central and eastern Europe. If the mutation occurred in a Jewish founder after the 
separation of the Yemenite, that would explain the absence of the G2019S only in this 
specific subgroup. Alternatively it is possible that the mutation was absent among the 
founders of the Yemenite subgroup simply by chance (genetic drift). In another subgroup 
of Jews, the Sephardim (Sephard means ‘‘Spanish’’ in Hebrew), which migrated to the 
Iberian Peninsula, the prevalence of the G2019S (in the context of haplotype 1) is similar to 
that of the Ashkenazi51. The precise origins of the Jewish communities of the Iberian 
Peninsula are unclear. Although the spread of Jews into Europe is most commonly 
associated with the Diaspora, it is thought that substantial Jewish immigration in Spanish 
regions probably occurred during the period of Roman occupation of Spain (after the 
Second Punic War, 218-202 B.C.), which would be much earlier than the Yemenite 
separation.  
In this picture it is not easy to speculate on the precise region of G2019S origin. It must be 
considered that patterns of migration, especially of Jews, often occurred in more separate 
waves, making their relation with the estimated age of the mutation complex.  
To explain the relative younger age of the Jewish haplotype compared to that estimated in 
North Africans, a possible hypothesis is that an ancient common founder ( ~3000 years ago 
, ~1000 B.C.) led to a descendant who served as a Jewish (Ashkenazi and Sephardic, but 
not Yemenite)  subfounder 120. 
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Further studies on the prevalence of the G2019S and haplotype analysis in genetically 
homogeneous North African populations (Arabs from Saudi Arabia, populations with 
presumed Phoenician ancestry [Syrians/Lebanese?], Berbers and Jewish subgroups) might 
provide important insight into the origin of the mutation125.   
Haplotype 2 
A different G2019S haplotype was identified in three families from Western Europe, but 
the geographic origin of this haplotype is less certain120. 
Haplotype 3 
The third haplotype has been found in Japanese patients carrying the G2019S116. This 
haplotype differs even across the markers closest to the mutation, which would suggest an 
independent origin of the mutation in Japanese and European populations rather than a 
single ancient founder. Interestingly, the haplotype 3 has also been observed  in a single 
sporadic Turkish patient53. This may be the result of a common ancestry (plausibly 
explained by the large centuries-long migration of the Turkic people across Central Asia) 
or coincidental presence of Japanese ancestors. Further screening and haplotype analysis in 
this country are warranted.  
 
 
Incomplete penetrance of G2019S 
 
Incomplete penetrance was already suspected for the mutations underlying the PARK8 
locus at the time of the linkage studies. Since G2019S represents the most frequent LRRK2 
mutation, most of the penetrance analyses have been performed on this specific mutation. 
Initially, a high penetrance for the G2019S mutation was reported: 17% at age 50 years and 
85% at 70 years41, and 33% at 55 years and 100% at 75 years46. However, the patients 
included in the analysis were from selected, large autosomal dominant familial PD, and 
probands were not excluded, leading to a marked overestimation.  
More recent analyses performed on Ashkenazi Jews revealed a lifetime penetrance of 
31.8% 44. A slighter lower penetrance (24% at 80 years) was estimated in an independent 
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group of U.S. and Ashkenazi Jews48 (without significant differences between the two 
groups). 
Moreover, a family-based study on 36 G2019S carriers, mainly from Italy, estimated a 
penetrance of 30% at 80 years126. The latter result was consistent with those found in the 
Ashkenazi Jews44. The International LRRK2 Consortium performed a penetrance study on 
the largest dataset of G2019S carriers. By analyzing a large sample PD patients and 
controls with and without the G2019S mutation, Healy et al. calculated a 28% risk of PD at 
59 years, 51% at 69 years, and 74% at 79 years for LRRK2 G2019S carriers. There was no 
difference in penetrance by sex or ethnic group127. It is worth underlining that, as in the 
Italian study126, also in this multicentric study the selection bias was minimized by 
excluding the probands and including the families of sporadic cases, when data were 
available for both parents. A second consortium also enrolled a large sample of familial PD 
and controls. G2019S was present in 29 families and the calculated penetrance (~67% at 85 
years) was substantially higher then that reported by the first consortium128.  
Finally, a penetrance study in Tunisian G2019S PD cases, after stratifying by homozygous 
(n=23) and heterozygous carriers, reported a penetrance consistently higher in 
homozygotes in each age group. Considering possible biases in estimating penetrance only 
from families, this finding, if true, would indicate a gene dosage effect, although the age of 
onset was not dissimilar between the two groups. This study needs replication in a larger 
independent dataset129. 
  
The reduced penetrance of this frequent mutation is in keeping with the LRRK2 G2019S 
being the most important genetic determinant, known so far, of sporadic PD. In populations 
like the Ashkenazi Jews, several studies consistently reported a lifetime penetrance of 
~30%. This can also be expressed in terms of risk (calculated as odd ratio) to develop the 
disease. For a Ashkenazi Jew who carries the G2019S the risk of developing PD increases 
of ~18 fold44. By analyzing the G2019S in North Africans, a lifetime odds ratio for 
developing PD of 48.6 (CI 11.2–211.0)43 has been calculated. 
Nevertheless, additional studies in different populations are warranted before G2019S 
genetic counseling can be implemented, since the precise estimation of the penetrance in 
some countries is still controversial.  
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It is possible that dissimilar results across the above-mentioned studies are not yet due to 
different methodological approaches, but actually revealed an intrinsic variability of the 
mutation penetrance among different subjects/families.  
The reduced penetrance suggests that the G2019S mutation itself is needed, but is 
somehow not sufficient for developing the disease. In this picture it is tempting to speculate 
that the presence of other genetic factors or simply stochastic events can act as modifiers of 
this (and may be other) LRRK2 mutation, thereby influencing the penetrance.  
The analysis of a few candidate genes involved in neurodegeneration as potential genetic 
modifiers of LRRK2 has been reported. The first to be explored was parkin, since patients 
who simultaneously harbored parkin mutations and LRRK2 G2019S have been mentioned 
in several studies57, 69, 91, 130-132. However, the clinical and cosegregation analysis of patients 
carrying heterozygous parkin mutations and the G2019S reveled that the combination of 
the two does not influence the symptoms or the age at disease onset. 
Recently, polymorphic variations in  the microtubule associated protein tau (MAPT) have 
been proposed to be significantly associated with age of disease onset in individuals with 
LRRK2 mutations133. Further analyses, especially on large samples and families carrying 
the G2019S, are warranted to identify genetic factors that can act as modifiers of LRRK2 
mutations.  
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Figure 2 
Schematic representation of the LRRK2 gene, the dardarin protein and its known functional domains. LRRK2 83 coding variants and three putative splice variants 
are grouped according to evidence of pathogenicity (see main text). 
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The R1441 mutational hot spot 
 
The LRRK2 R1441 residue is the second most common spot of pathogenic LRRK2 
mutations, after G2019S. Three non-synonymous substitutions (R1441C, R1441G and 
R1441H), and the synonymous R1441R have been reported in several patients.  
 
R1441C – the second most frequent pathogenic LRRK2 mutation 
 
This mutation (c. 4321C>T) represents the second known most common mutation of the 
LRRK2 gene. Its pathogenic role was clear when it was firstly shown to cosegregate with 
PD in the PARK8-linked “Family D” (Western Nebraska)7. Cosegregation was consistent 
also in smaller PD families from Germany7, 83, Italy65, Belgium86, US41, 128 and Iran55. The 
mutation has also been reported in a few other families, but additional affected relatives 
were not available for cosegregation analysis58, 65, 86, 134. The R1441C is also found among 
sporadic cases and has been reported in patients from Italy66, Sardinia73, Russia (Slavic 
origin)92, China135 and Belgium86. The variant was absent in large cohorts of ethnically 
matched controls (>1000 German, 530 Italian, 208 Sardinian, 400 Chinese, 178 Belgian 
and 300 U.S.). Being the nucleotide mutated close to the splice acceptor (+4 from the AG), 
cDNA analysis was performed in order to exclude deleterious consequence at the transcript 
level65. 
Haplotype analysis of LRRK2 R1441C carriers from 20 families of different geographical 
areas revealed in total four classes of haplotypes. Only for the two major haplotypes could 
the phase be established136. A first haplotype was identified in all Italian carriers, as well as 
in German, Spanish, and American patients. 
A second haplotype was present in the American Family D (Western Nebraska) and in all 
Belgian R1441C families. A German and an Irish patient shared a third haplotype for 
which phase could not be unambiguously determined. Finally, a Chinese proband carried 
alleles that could not be assigned to any of the previous three haplotype classes.  
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The phenotype associated with this mutation is similar to that of classic PD136. The 
mutation exhibits incomplete penetrance, which could explain its presence in sporadic 
cases, but calculations performed so far must be interpreted with caution as only a small 
number of R1441C mutation carriers have been identified until now. 
Intriguingly, the neuropathology associated with the R1441C mutation in “Family D” 
(Western Nebraska) revealed α-synucleinopathy (presence of Lewy bodies) in one member, 
a tauopathy with neurofibrillary tangles and Progressive Supranuclear Palsy (PSP)-like 
distribution in a second affected member, and loss of neurons with no intracytoplasmic 
neuronal inclusions in a third37. 
 
R1441G – a founder pathogenic mutation in the Basques 
 
The LRRK2 R1441G (c. 4321C>G) was initially described in patients with autosomal 
dominant late-onset PD in PARK8-linked families of Basque ethnicity6. The Basques are a 
homogeneous ethnic group who historically were isolated by linguistic and geographical 
barriers. The first report on the frequency of this mutation in Basque  PD (~8% of familial 
cases)6 and the absence in other large populations screened (except for a U.S. patient 
reported to be of Hispanic descent49) suggested  that this variant was population specific. 
Further studies investigated the prevalence of this mutation in Basque. One group detected 
the R1441G in 16.4% and 4.0% of familial and sporadic Basque PD, respectively137; while 
a more recent study reported a prevalence of 46% in familial Basque patients and 2.5% of 
sporadic cases62. It has also been identified at lower frequencies in patients from nearby 
provinces in Spain who did not report Basque ancestry (6% of non-Basques living in the 
Basque countries62, 2.7% in Asturias138, 0.7% in Catalonia58, two families from the 
neighbouring region of Navarre, and one from la Rioja59), while is rare in Cantabria60. 
Haplotype analysis on R1441G carriers from Basque and neighborhood regions59, 137, 139 
indicates that this mutation occurred in a single common ancestor, which in one study was 
estimated to have lived 1,350 (95% CI, 1,020–1,740) years ago139. Since the Basque 
population has a history of emigration to Europe, and North, Central and South Americas, 
it would not be surprising to find isolated cases in those countries. However, recently a 
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single case from Uruguay carrying the R1441G, who denied her ancestry as European, has 
been reported with a different haplotype than the Basque, suggesting in this case an 
independent mutational event104. 
The clinical phenotype of the patients with the R1441G mutation is similar to that of 
classical late onset PD36, 58, 59, 62, 137, 138. A poor response to bilateral deep brain subtalamic 
stimulation in patients with the R1441G compared to idiopathic PD has been reported140, 
but  confirmation in a larger number of carriers treated with this approach is warranted.  
The only post-mortem material from a patient with the R1441G (Basque) mutation has 
briefly been described. Loss of dopaminergic neurons in the substantia nigra, free 
neuromelanin in the neuropil and absence of α-synuclein-, hyperphosphorylated tau- and 
ubiquitin-immunoreactive inclusions were mentioned141.  
 
R1441H and R1441R – uncommon, but also likely pathogenic 
 
This variant, c.G4322A on LRRK2 cDNA, occurs immediately adjacent to the two 
previously reported pathogenic mutations, c.C4321T (R1441C) and c.C4321G (R1441G), 
resulting in a different substitution of the same amino acid residue (R1441H). 
R1441H has been described in a U.S. PD family but only the proband and an unaffected 
sibling were available for testing134. Is was also reported in PD families from Crete77, 
Portugal57 and Taiwan80, all not large enough to demonstrate definitive cosegregation with 
the disease.  
Haplotype analysis of the above mentioned R1441H carriers showed diversity suggesting a 
number of independent founders142. Subsequently, the R1441H mutation has been 
identified in two cases from Australia, both of British origin and with a possible common 
haplotype, although in these cases the phase was not assessed117. A further proof in favor of 
a pathogenic role of this variant came from the identification of R1441H in two slightly 
larger French families 68.  
R1441H was not found in 281 U.S., 300 Cretans, 200 Portugueses, 174 Europeans and a set 
of 1,000 control samples (600 North Americans, 200 Taiwaneses, 200 Norwegians, 200 
Irish, and 200 Spanish). Moreover several studies screened by sequence the LRRK2 exon 
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31 in a large sample of healthy controls (>3000 Caucasian6, 7, 65, 86) in order to check for the 
R1441C and G, and none reported mutation in the adjacent nucleotide. 
The clinical presentation of affected R1441H carriers appears to be similar to typical 
Parkinson’s disease with an age at onset range of 32–66 years. All display levodopa 
responsive parkinsonism, however, the disease in one of the siblings from the Greek 
R1441H family appeared to transition into a progressive supranuclear palsy-like disorder77. 
 
To further highlight the nature of codon 1441 as a mutational hotspot, two groups reported 
a R1441R (c.C4323T) in a sporadic PD patient93 from Russia and a PD patient with 
ascertained LB pathology who additionally developed dementia and dysautonomia 
(PDD)143. As for the R1441H we can indirectly assume that the variant is rare in the 
Caucasian population, since sequencing controls for the other mutations at the same codon 
did not reveal any R1441R carriers. This variant is predicted to lead to a synonymous 
substitution, which would suggest a non-pathogenic role. Moreover, being the nucleotide 
change close to the splice site, cDNA analysis from brain of the PDD patient was 
performed and did not reveal any aberrations on the LRRK2 transcript143.  Taken together 
these results suggest that R1441R is likely to represent a rare but non-pathogenic 
polymorphism.  
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The other LRRK2 variants: which are pathogenic? 
 
Besides the most recurrent G2019S and R1441 C/G/H, more than 50 different LRRK2 
sequence variants have been reported in familial and sporadic PD cases so far; moreover 
few novel LRRK2 substitutions have been found in healthy control subjects only (Figure 2). 
The Y1699C and I2020T mutations are considered as definitely pathogenic. The Y1669C 
was identified in two independent large families, the Lincolnshire kindred6, 78 (family PL) 
of European ancestry, and “Family A” (German-Canadian)7, 37. Interestingly, the detailed 
analysis of these families revealed not only an interfamilial but, surprisingly, an 
intrafamilal variability in clinical and pathological features (see paragraph on 
Neuropathology). The I2020T was identified in “family 32”7 and “T10738”85, both of 
German ancestry, and absent in more than 1000 German control subjects. Additionally the 
same mutation was identified segregating in the large PARK8-linked Sagamihara kindred42  
and in two smaller Japanese families coming from the neighborhood of the Sagamihara 
region47. 
The role of several other variants remains unclear, since often no family members were 
available to assess cosegregation and a limited number of ethnically matched controls was 
screened. 
Some of these substitutions are recurrent, like the L1114L in “family 38”7 (two affected 
siblings were carriers) and  in a Irish sporadic patient144; the same variant has been detected 
in an unaffected sibling but not in the correspondent proband, making its pathogenic role 
uncertain144. The L1114L (c.3342A>G) affects a nucleotide close to the splice donor of 
exon 24, but so far no analysis on cDNA has been reported.  The I1371V has been reported 
in four independent probands65, 68, 132, but convincing evidence of cosegregation is still 
missing. The I1371V is absent in large number of French68 and US controls, and was not 
tested in Indians from where one patient carrier comes132, and  it was present in one (out of 
416)  Italian control subject sampled at the age of 55 years who might be still at risk of 
developing PD65. Similarly, the R1067Q mutation, has been reported in one sporadic 
Chinese patient145, two sporadic Japanese patients146 and a single Japanese-American 
control who at his last assessment at 83 years of age displayed no signs or symptoms of 
parkinsonism and reported no family history of PD.  
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While the role of the last three variants remains controversial, a fourth LRRK2 mutation, 
T2356I, identified in a small family from UK78 with at least two affected carriers, in a 
single sporadic case from US96 and in a sporadic Dutch patient87, and absent in more than 
1300 ethnic matched controls, is likely to be pathogenic. Interestingly, the threonine at the 
position 2356 is not completely conserved among LRRK2 orthologues (see paragraph on 
LRRK2 Protein) 
Of the remaining private variants, ten display some evidence of cosegregation with PD, 
although in small families (E10K147, E334K147, Q930R85, Q1111H147, I1122V7, I1192V147, 
S1228T85, A1442P117, L1795F147, R1941H78). 
Twenty-three had no cosegregation data available (S52F68, A211V148, N363S68, M712V98, 
I810V68, Q923H106, S973N88, A1151T89, L1165P95, K1468E86 V1613A92, R1728L98, 
R1728H98,M1869V149, E1874X149, Y2006H69, I2012T47, T2031S69, T2141M98, R2143H98, 
Y2189C86, V2390M150, L2466H98).  
Three intronic variants, proposed to be splice mutations (IVS20+4delGTAA96, 
IVS31+3A>G55, 134, IVS33+6T>A145) have been reported in patients, but never in controls. 
Although expression of the IVS20+4delGTAA variant in the pSPES splicing vector yielded 
a cDNA fragment lacking the exon 19, the precise effect of all these variants on patients’ 
cDNA is still unclear. Recently the IVS31+3A>G55, 134 has been studied in an Iranian 
family, where the variant did not segregate with PD, suggesting that it likely represents a 
non-pathogenic variant. The IVS33+6T>A was found in one patient who developed typical 
parkinsonian signs after an 8-year course of isolated essential tremor, which rather differs 
from the classical PD course associated with LRRK2 mutations. The role of all these 
intronic variants remains to be elucidated. 
K544E148, S1096C85, H1216R68, R1483Q86 and M1869T80 (the last reported also in a 
sporadic case from US144) represent variants which are absent in large number of controls 
but with an incomplete cosegregation with PD, which would suggest either no association 
with PD or the presence of phenocopies in those families. 
The role of the R1325Q also remains unclear. It was identified in a Belgian family where 
the mother of the proband was affected by initial tremor and is a carrier for the variant in a 
homozygous state86; the same change has been reported in a French familial PD case, but 
no family members were available for cosegregation68. 
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Finally, several variants, initially not present in SNP databases, have been reported in PD 
cases and controls with similar frequencies (L119P7, 65, A419V149, P755L149, 151-153, 
R793M7, 81, 85, 95, 144, T1410M68, P1446L146, V1450I146, R1514Q7, 65, 154, 155, P1542S7, 65, 80, 
M1646T7, 65) and some only in healthy subjects (C228S, A716V, K871E, L1870F, 
E2395K)98. These most likely represent non-pathogenic polymorphisms. 
 
In conclusion, the LRRK2 gene displays a high polymorphic content in terms of single 
nucleotide substitutions. No deletions or duplications have been identified until now. 
Variants identified in patients are located in almost all exons. However, most of them still 
lack a definite proof of pathogenicity. This has direct practical consequences for the genetic 
studies. LRRK2 is a large gene containing 51 exons. A time/cost-saving strategy to perform 
the mutational analysis could be to first screen for the frequent G2019S mutation. If 
negative, other validated mutations (R1441G/C/H, I2020T and Y1699C) can be tested next. 
Where a considerable number of affected family members are available for testing, an 
option is to screen the entire LRRK2 gene, which raises the possibility of discovering one 
of the above reported doubtful variants, or even a novel mutation that could be tested for 
cosegregation in order to verify its pathogenic role.  
Concerning the significance of these data for the genetic counseling, it is worth to consider 
that screening the whole coding region or single variants of uncertain role in unselected 
cases is still a matter of debate, since the identification of any variant would result in more 
questions than answers for both clinicians and patients. 
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The clinical phenotype associated with LRRK2 mutations 
 
Mutations in PD-causing genes such as parkin, PINK1 and DJ-1 were mostly associated 
with some clinical features that differ from classical PD, like an early age of symptoms 
onset and a slow disease course. Differently, mutations in α-synuclein have been associated 
with both, classical and aggressive forms of the disease and some mutation carriers 
developed symptoms more typical of diffuse LB disease, rather than PD156. In this scenario, 
the LRRK2 associated phenotype represents an exception. 
Reviewing the core features of 356 patients with LRRK2 G2019S one can summarize that 
the associated phenotype is characterized by asymmetrical, tremor-predominant 
parkinsonism with bradykinesia and rigidity that responded to dopamine replacement and 
functional neurosurgery. Tremor in this study was reported to be more common in patients 
with LRRK2 G2019S-associated PD than in idiopathic PD. The age of PD onset for all 
LRRK2 mutation carriers is broad, with an average of ~58·1 years ± 14·0, which does not 
differ significantly between patients with LRRK2 G2019S (57·5 years ± 13·9 years) and 
carriers of all LRRK2 non-G2019S mutations (59·9 years ±13·8 years). Moreover, there is 
no difference in the frequency of the G2019S mutation in probands with early vs late onset 
disease66. The disease duration, the rate of disease progression in LRRK2 mutation carriers 
(measured by the time to progression through each point on the Hoehn and Yahr scale), and 
the clinical response to L-Dopa is similar to those in patients with idiopathic PD127. Several 
PET studies documented in LRRK2 G2019S patients a reduced uptake of tracers for the 
membrane dopamine transporter (DAT) and vesicular dopamine transporter (VMAT2), as 
well as a reduction of 18F/dopa uptake in the striatum with a classic pattern of asymmetry 
with the putamen more severely affected than the caudate78, 119, 157.  
At least 29 homozygous carriers of the G2019S have been described so far, and they 
display a mean age of disease onset and phenotype features similar to the heterozygous 
patients. 129 40, 43, 46, 48, 95, 100, 127 
From the currently available data, one can conclude that there are not clinical features that 
distinguish LRRK2 associated PD from idiopathic Parkinson’s disease.   
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The neuropathology associated with LRRK2 mutations 
 
Mutations in LRRK2 are associated with a pleomorphic range of pathologies, although the 
LB-positive pathology is the most common pattern, particularly for the G2019S 
mutation.37, 78, 158-160 
The presence of LB positive pathology was briefly mentioned in three cases included in 
one of the first papers on this mutation39. Interestingly one patient showed signs of 
pathological aging with neocortical plaques and occasional neurofibrillary tangles.  
In a large screen of 405 LB-positive brains, 8 (~2%) have been found to be carriers of the 
G2019S mutation, including 4 with brainstem-type, three with transitional-type, and 1 with 
diffuse LB pathology160. In two G2019S positive brains, Alzheimer-type pathology was 
also present and it was of enough severity to make a concomitant pathological diagnosis of 
Alzheimer’s disease. 
A further study on 80 brains with PD or LB dementia screened for the G2019S mutation, 
and 3 were found to be carriers158. Typical brainstem-type LB-positive pathology was 
found in one, while the Lewy body variant of Alzheimer’s disease was diagnosed in the 
second. The third brain showed only cell loss in the substantia nigra and locus coeruleus, 
but no α-synuclein inclusions were detected. There were only rare tau-positive tangles and 
occasional plaques. No other ubiquitin positive inclusions were present either.  
Finally, we described a neuropathological study in an Italian PD case carrying a different 
LRRK2 mutation, I1371V, who showed typical ubiquitin- and α-synuclein–positive Lewy 
body pathology159. 
 
The atypical phenotypes 
 
Even though most of the patients with LRRK2 pathogenic mutations have clinically and 
pathologically typical PD, some exceptions with different clinical and/or neuropathological 
features exist in the literature.  
One member of the original Sagamihara family, later found to carry the I2020T mutation, 
developed pathologically-confirmed striatonigral degeneration, a variant of the multiple 
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system atrophy (MSA) which is known to be associated with α-synuclein-positive brain 
pathology32. A pattern of pure nigral degeneration was reported in other family members32. 
Recently, the authors conducted a clinical and neuropathologic follow up of the family, and 
reported the finding of pure nigral degeneration in two additional affected family members 
and classical Lewy body pathology in a third case, all carrying the I2020T mutation161. 
Furthermore, the “family A” (German-Canadian), associated with the LRRK2 Y1699C 
mutation, included two members who manifested primarily with dementia and two 
individuals who developed parkinsonism associated with a distal limb muscle weakness, 
atrophy and fasciculation7. Neuropathological examination of the latter showed evidence of 
nigral neuronal loss with gliosis and spinal cord anterior horn neurodegeneration with 
ubiquitin-immunoreactive axonal spheroids, reminiscent of amyotrophic lateral sclerosis 
(ALS)37. Interestingly, an autopsy performed in the British family with PD and the same 
Y1699C mutation, the Lincolnshire kindred, revealed LB-positive pathology in the brain 
and olfactory bulb, as observed in classical PD78. 
Two carriers of G2019S were identified among 1,179 LB-negative brains, including 326 
progressive supranuclear palsy, 43 multiple-system atrophy, 654 Alzheimer’s disease, and 
156 healthy control brains. One G2019S carrier was a sporadic case with both clinical and 
neuropathological confirmed Alzheimer disease160 .  
G2019S has been described in a Brazilian sporadic patient who developed both Parkinson’s 
disease and Alzheimer disease162. Another patient carrying the G2019S had a clinical 
diagnosis of corticobasal syndrome (CBS), with some extrapyramidal symptoms and no 
response to levodopa95. A 77-year-old patient with a 14 year history of PD disclosed at the 
pathological examination mild neuronal loss in the substantia nigra without α-synuclein, 
tau or ubiquitin cytoplasmic inclusions163. Again, a patient with the G2019S developed no 
symptoms of parkinsonism and presented neuropathology features typical for FTD with 
ubiquitin-immunoreactive inclusions. This patient had a family history of essential tremor, 
but not of parkinsonism or dementia143. 
Last, a family from U.S. with parkinsonism, with poor response to levodopa (Family SK) 
and dementia,  has been reported to carry the G2019S mutation164. Neuropathological 
analysis of the proband’s brain revealed PSP-like tau pathology similar in type, quantity, 
and distribution to that observed in one member of “Family D” with LRRK2 R1441C37, 164. 
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The occasional association of LRRK2 mutations with MSA-like pathology, dementia and 
ALS-like phenotype prompted several groups to determine the frequency of LRRK2 
mutations in neurodegenerative disorders other than PD. The most studied mutation was 
the G2019S, although also the Y1699C, R1441C and I202T have been screened in several 
studies. 
The LRRK2 G2019S was absent in hundred of cases with Alzheimer disease from U.S.165, 
Norway166, Italy167 and Ashkenazi Jews52. 
Moreover, the mutation has not been identified in large cohorts of Caucasian and Asian 
patients, mostly with diagnosis of dementia, but also with MSA, PSP, FTD, CBD, vascular 
dementia and Lewy body dementia84, 88, 135, 168-171. 
The G2019S, I2020T and I2012T were also absent in 272 patients with the diagnosis of 
essential tremor172. 
In conclusion, all the above reported data strongly suggest that LRRK2 mutations are 
specific for PD, but the associated pathology might differ considerably, even between cases 
with the same mutation belonging to the same family, suggesting an important role of still 
unknown modifiers. Although most of the patients had the classical findings of nigral cell 
loss, gliosis and Lewy bodies, some had no Lewy bodies, suggesting that the LB pathology 
might not be the unique pathological hallmark of the disease. Moreover few LRRK2 
mutation carriers displayed a spectrum of features more reminiscent of tauopathy.  
These observations suggest that the classical definition and boundaries of the disease 
should be reconsidered.  
 
Association studies on LRRK2 
 
In the past few years many groups put special effort in search of common risk factors for 
complex diseases. Among these, Parkinson’s disease and other neurodegenerative disorders 
have been extensively studied. However, even using high throughput techniques allowing 
to genotype hundred of thousand of SNPs and covering the whole genome in cases and 
controls (genome wide association studies, GWA), no reproducible risk loci have been 
reported so far. 
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One caveat is that the GWA approach can be problematic because the massive number of 
statistical tests performed presents an unprecedented potential for false-positive results. 
After the discovering of mutations in the LRRK2 gene, several studies aimed to explore 
whether common variant of this gene could represent a risk factor for PD. 
Two association studies on LRRK2 have been performed in Caucasians. The first enrolled 
340 PD patients and 608 controls from Germany. 121 SNPs (81 tagging SNPs) were 
genotyped attempting to represent the complete DNA variation of the LRRK2 gene173. The 
second study analyzed four common coding SNPs (L953L, H1398R, G1624G and 
T2397M) in 250 controls and 121 unrelated PD, mostly with early onset and positive 
family history132. Neither of these studies revealed any evidences of association between 
PD and the LRRK2 SNPs at both allelic and genotypic levels. 
In 2005, one study performed in Singapore yielded a significant association. A set of 21 
tagging SNPs covering the LRRK2 gene were genotyped in 466 sporadic PD and 374 
control individuals all of Chinese ancestry. The authors identified a common haplotype that 
was highly overrepresented within cases (p = 0.005) and, when present in two copies, 
significantly increased the risk of PD (OR = 5.5, 95% C.I. = 2.1–14.0, P = 0.0001)174. 
However, no LRRK2 variants within the risk haplotype were reported as the biologically 
relevant factors. 
 
The G2385R variant 
 
The LRRK2 G2385R represents the fist common genetic risk factor for PD in the Asian 
population. This variant was first reported in a small PD family from Taiwan80. Evidence 
for cosegregation with PD in that family was limited due to the small pedigree size; 
however, the mutation was reported to be absent in 200 ethnically matched controls, and 
therefore, interpreted as putatively pathogenic. At that time very limited data were 
available on the nature and frequency of LRRK2 mutations and on the polymorphism 
content of the gene in patients from Asia.  
Chapter 1 
 39 
We and other groups first conducted a mutational screening of three known PD-causing 
mutations (I2012T, G2019S, and I2020T) which appeared to be very rare or absent in 
Asian PD patients42, 109, 111, 112. 
In order to identify other LRRK2 variants which could play a role in PD in Asian 
populations we screened by sequencing the whole LRRK2 coding region and splice sites in 
15 Chinese Han patients with sporadic PD. Four of the identified coding variant (A419V, 
P755L, M1869V which were novel substitutions, and the G2385R) were tested for 
association with PD in our entire sample of 608 Chinese Han cases and 373 ethnically 
matched controls. 
The heterozygosity for the G2385R variant was significantly higher among PD cases (61 
heterozygous carriers out of 608 tested cases) than controls (18 heterozygous carriers out of 
373 tested controls [nominal p value=0.004, corrected for multiple comparisons=0.012; 
permutation test, p=0.02 (5,000 replicates); gender- and age-adjusted odds ratio 2.24, 95% 
C.I.: 1.29–3.88]. This suggested that the G2385R variant, or another variant in linkage 
disequilibrium, is associated with PD in the Taiwanese population.  
Since then, five association studies on Chinese Han population from Taiwan, Singapore 
and mainland of China replicated this finding with a similar size effect (Table 2). An 
additional study on Chinese recruited in Hong Kong reported a prevalence of G2385R in 
early and late onset PD of ~8.5%, and not in controls175. However, this study was not 
suitable to test association due to the small number of subjects. 
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Study  Geographical Ethnicity  PD  CTR  OR (95% CI) p value  
  location 
 
 
Di Fonzo et al.  Taiwan  Chinese Han 61/608 (10%) 18/373 (4.8%) 2.20 (1.28-3.78) 0.012 
(2006) 
Tan et al.  Singapore  Chinese  37/495 (7.5%) 18/494 (3.6%) 2.14 (1.20-3.81) 0.002 
(2006) 
Fung et al.  Taiwan  Chinese Han 27/305 (9%)  1/176 (0.5%) 17.00 (2.29-126.20) 0.0002 
(2006) 
Farrer et al.  Taiwan  Chinese  34/410 (9.3%) 13/335 (3.9%) 2.24 (1.16-4.32) 0.014 
(2007) 
Funayama et al. Japan  Japanese  52/448 (11.6%) 22/457 (4.8%) 2.60 (1.55-4.35) 0.0002 
(2007) 
Tan et al.  Singapore  Malay  2/98 (2%)  2/173 (1.2%) 1.75 (0.25-12.85) 0.6 
(2007) 
    Indian  0/66 (0%)  0/133 (0%) 
  
Li et al.  Shanghai  Chinese Han 14/235 (6%)  0/214 (0%)  28.08 (1.66-473.72) <0.001 
(2007)  
An et al.  Mainland  Chinese Han  71/600 (11.8%) 11/334 (3.3%) 3.94 (2.06-7.55) <0.001 
(2008)  of China 
Zabetian et al. Japan and  Japanese  69/601 (11.5%) 101/1628 (6.2%) 1.96 (1.42-2.70) <0.001 
(2009)  U.S.   
 
Total      367/3800 (9.6%) 168/4184 (4.4%) 2.55 (2.10-3.10) <0.001 
 
 
 
Table 2. Overview of results of LRRK2 G2385R association studies in PD. Number of subjects homozygous 
or heterozygous for the G2385R and total number of individuals studied are reported. OR: odds ratio with 
95% confidence interval (CI) 
 
 
Interestingly the association was also reported in Japanese PD patients and controls, giving 
a risk of developing PD increased of ~2-fold116, 176. The clinical presentations of all 
G2385R carriers showed no difference from typical idiopathic PD with definite asymmetric 
onset, bradykinesia, resting tremor and rigidity. All carriers showed good response to 
dopamine replacement therapy149, 176-179. A meta-analysis on five studies suggested that the 
G2385R has a small but significant effect in lowering the age at onset of PD180. In one 
study a slightly higher prevalence in females with early onset was reported178.  
Two groups performed a haplotype analysis of G2385R carriers in a cohort of Chinese Han 
from Taiwan177, 178. A single common haplotype shared by all the carriers has been 
identified, likely originated from a single ancestor who lived approximately 4800 years 
ago. Also all Japanese G2385R carriers shared the same haplotype, with a set of markers 
(D12S2516, D12S2519 and D12S2521) which overlapped with the Chinese haplotype.  
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This might suggest that the G2385R of Chinese Han and Japanese ancestry has arisen from 
a common ancestor116.  
 
The R1628P variant 
 
The LRRK2 R1628P has been identified in a multicentric study which combined 1986 
Chinese individuals from 3 independent centers in Taiwan and Singapore, and so far 
represents the second more frequent genetic risk factor for PD in Asia181. This variant was 
approximately twice as frequent in affected individuals as control subjects [~6% of PD and 
~3.5% of controls, odds ratio 1.84, 95% C.I.: 1.20–2.83, nominal p value= 0.006] 181.  
This finding was replicated in two independent Chinese Han cohorts from Singapore182 and 
Taiwan183 [8.4% vs 3.4% odds ratio 2.5, 95% C.I.: 1.1-5.6 p=0.046 and 7.4% vs 3.7% odds 
ratio 2.13, 95% C.I.: 1.29-3.52 p= 0.004, respectively]. On the contrary the R1628P is rare 
in Japan and in non-Chinese Asians146, 181, 184. 
Haplotype analysis strongly indicates that carriers of the R1628P variant share an extended 
haplotype, indicative of a founder effect181. The mutation has been estimated to arise ~2500 
years ago and, in contrast to the older G2385R has remained confined to subjects of 
Chinese Han ethnicity. 
Like for the G2385R, the clinical phenotype of the affected R1628P carriers is that of 
typical late onset L-dopa responsive PD181, 183, 184. 
Taken together, these studies indicate for the first time that common population specific 
genetic risk factors for PD exist. The association of both LRRK2 variants with PD in Asia 
has been extensively confirmed in independent dataset of patients. These findings open 
several opportunities of studies for researchers and clinicians. Discovering how those 
variants can increase the risk of death of dopaminergic neurons might provide important 
insight into the pathogenesis of the disease. Other interesting prospects can be provided in 
clinical practice, for example studying the effect of neuroprotective drugs in large cohorts 
of asymptomatic carriers of these two LRRK2 variants, in order to explore whether the risk 
of developing PD would decrease in the treated subjects.  
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Functional Studies on LRRK2 
 
The LRRK2 protein 
 
 
Figure 3 
Schematic representation of the LRRK2 protein and its known functional domains. The domain boundaries 
are indicated by the residue numbers. Abbreviations: LRR, leucine-rich repeat domain; Roc, Ras of complex 
(GTPase).,COR, C terminal of Roc.  
 
 
LRRK2 (also named dardarin) is a 2,527-amino acid protein which belongs to a newly 
identified protein family termed ROCO. LRRK2 has a complex structure, which includes 
several types of repeats and three large domains, called Roc (Ras in complex protein) , 
COR (C-terminal of Roc), and a mixed lineage kinase domain185. Two known protein-
protein-interaction domains are present, the leucine-rich repeats (LRR) before the Roc 
domain, and the WD40 in C-terminus.  
ROCO family genes are present in both prokaryotes and eukaryotes, but the function of the 
encoded proteins is still unknown. The paralogue LRRK1 is the closest relative of LRRK2; 
however, it largely differs from LRRK2 at its N-terminus. Recently a phylogenetic analysis 
on LRRK2 revealed an ancient orthologue of LRRK2 in N.vectensis186. By aligning the 
LRRK2 orthologue it was possible to recognize a specific conserved N-terminus repeat 
structure which can be considered as Armadillo-like helical domain. This kind of structure 
is considered to be a protein-protein interaction surface. 
The newly identified LRRK2 conserved N-terminus region is absent in LRRK1, and 
interestingly also indicate that no true orthologue of LRRK2 exists in protostomes like 
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Drosophila melanogaster and Caenorhabditis elegans186, that could be better to considered 
as LRRK1 orthologues.   
 
In silico analysis 
 
The LRRK2 residues replaced by the definitely pathogenic mutations are highly conserved 
among LRRK2 orthologues suggesting important roles on those residues for the LRRK2 
function and possible loss of function as effect of the mutations (figure 4). Regarding the 
substitutions that are still of uncertain pathogenicity the conservation during evolution is 
variable. However, especially for mutations which would result in a gain of protein 
function, the conservation of the residues is not an absolute requisite for pathogenicity. If a 
definitely pathogenic role of those less conserved variant will be established, this would 
support a hypothesis of a gain of function effect.    
  
 
 
Figure 4 
Multiple alignment of LRRK2 protein with orthologues. The most likely and definite pathogenic mutations 
are indicated. 
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mRNA expression patterns 
 
The human LRRK2 transcript is ubiquitously expressed, with highest levels in lung and 
kidney187. The expression of LRRK2 mRNA has been examined in neurologically normal 
human brains, where it was found to be expressed in both dopaminergic and non 
dopaminergic areas, which would suggest an important role in basic cellular functions 
(reviewed in 188). 
 
In vitro studies 
 
Several studies on the expression of the LRRK2 protein in brain areas and sub-cellular 
compartments have been published (reviewed in 141). The major caveat is the specificity of 
LRRK2 antibodies, most of which have so far been unable to detect on western blot 
analysis a single band corresponding to the endogenous LRRK2 protein141. This technical 
limit has a major impact on the results of immunohistochemistry and sub-cellular 
localization studies as well. Additionally, the dissimilar specificity of the various LRRK2-
antibodies used so far  (together with the different experimental procedures) could also 
explain the different results in detecting LRRK2 in Lewy bodies158, 189-193, and tau-
immunoreactive inclusions160, 190, 194. 
In vitro studies on human LRRK2 revealed that the Roc domain, which exists as a dimer195, 
has a GTPase activity and, by binding GTP196-200, it activates the kinase domain200. 
The purified LRRK2 protein, through its kinase domain, is able to autophosphorylate or to 
phosphorylate a generic substrate201, 202. The G2019S mutation lies within the activation 
segment of the kinase domain of LRRK2. Interestingly, the activity of a large variety of 
protein kinases is controlled by activation segment conformation, whereby phosphorylation 
of this segment leads to a conformational switch of the kinase from an ‘off’- to an ‘on’-
state203. Both overexpressed and purified LRRK2-G2019S increase the kinase activity in 
terms of autophosphorylation 189, 201, 202. Initial studies reported that R1441C and R1441G 
mutations, which lie within the GTPase domain, decrease GTPase activity196, 197, and, 
interestingly, lead to an increased kinase activity197 , although the latter observation was not 
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confirmed in a further study204. An increased kinase activity has been found by 
overexpressing LRRK2 Y1699C and I2020T mutants as well199, 205; however, the effect of 
the Y1699C was not confirmed elsewhere204.  
The results of cell culture experiments are derived by using overexpressed LRRK2 and 
therefore should be considered with caution. Mutations in LRRK2 which lead to increased 
kinase activity are also associated with formation of toxic aggregates 189 and increased 
apoptotic cell death in dopaminergic cell lines and primary neurons198. In addition, LRRK2 
kinase-dead constructs reduced neuronal toxicity198.  
Mutations affecting the kinase domain (G2019S and I2020T) might play a crucial role also 
in neurite outgrowth, leading to dramatic reductions in neurite length and branching of 
axons and dendrites206; on the contrary, overexpressing the kinase-dead K1906M construct 
or LRRK2 short hairpin RNA leads to an increased neurite length206. 
In summary, these results, though considering the limits of the current experimental 
procedures, suggest that the mutations leading to a reduced GTPase or an increased kinase 
activitiy would result in apoptotic cell death. Whether this effect has to be considered a 
gain or a loss of protein function is still controversial, since the final outcome of the 
LRRK2 activity is still unknown. Moreover, only the effect of the proved pathogenic 
mutations has been studied so far. It would be interesting to explore the functional 
consequence of other variants, at the moment classified as possible pathogenic, like the 
IVS20+4delGTAA, IVS33+6T>A and E1874X, which at least in silico are predicted to 
result in a truncated protein. Most of the observations still need further confirmation in 
more physiological models to clarify the normal function and the consequence of the 
mutations of the LRRK2 protein. 
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Animal models 
 
• C. elegans 
 
The C. elegans knockout for LRK-1 gene (which was considered to be a LRRK2 
homologue) displays an aberrant sorting of synaptic vesicle proteins to axons207 and a 
hypersensitivity to endoplasmic reticulum stressor tunycamicin208. In addition, 
overexpressing human LRRK2 strongly protects C. elegans against the mitochondrial toxin 
rotenone. The G2019S LRRK2 construct also protected against rotenone toxicity, but to a 
lesser degree than wild-type LRRK2, while knocking down LRK-1 potentiated rotenone 
toxicity. These data suggest a role of  LRRK genes in mitochondrial physiology209.  
 
• D. melanogaster  
 
The first transgenic Drosophila was generated using FLAG-tagged transgenic alleles for 
wild type LRRK and a mutant containing R1069C mutation corresponding to the 
pathogenic human LRRK2 R1441C mutation. No deleterious effect of the mutation was 
detected.  
On the contrary, loss-of-function dLRRK mutations induced locomotive impairment and a 
reduction in tyrosine hydroxylase (TH) immunostaining within dopaminergic neurons, as 
well as loss of fertility in females210. 
A second study described a transgenic Drosophila with a P-element insertion in the dLRRK 
gene which results in a truncated protein lacking the C-terminal kinase domain. 
Experimental data demonstrated that dLRRK kinase activity is not required for normal 
development and growth211. 
Finally transgenic Drosophila overexpressing either wild-type human LRRK2 or LRRK2-
G2019S were generated. Neuropathological analysis revealed that, at 1 day after eclosion, 
there were no differences in anti-TH-positive staining between of control and LRRK2 or 
LRRK2-G2019S flies. However, at 5 weeks of age, anti-TH staining decreased 
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significantly in flies expressing either wild-type or mutant LRRK2-G2019S. There was 
statistically significant TH-positive neuronal loss in all of the DA clusters examined. In 
addition, mutant LRRK2-G2019S caused more TH-positive neuronal loss than wild-type 
LRRK2 at equivalent expression levels. The expression of the human WT and mutant 
LRRK2 in neurons produced also locomotor dysfunction and early mortality. Expression of 
mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than 
expression of equivalent levels of wild-type LRRK2212. 
 
 
• Rodents 
 
LRRK2-knockout mice213, 214, and bacterial artificial chromosome (BAC) transgenic mice 
expressing murine FLAG-tagged WT Lrrk2197 have been briefly mentioned in several 
papers, but their detailed descriptions are still lacking. A conditional Lrrk2 G2019S mouse 
model has been created and it was useful to observe LRRK2 interacting with Hsp90 in 
vivo215. However, the human LRRK2 G2019S mice did not shown obvious 
neuropathological or motor abnormalities at 12 months of age, although primary 
hippocampal neurons derived from the mice displayed retarded axon outgrowth during 
neuronal morphogenesis215.  
Electroporating Lrrk2 WT and mutant cDNA expression constructs in neural progenitors of 
the periventricular region of rat embryos resulted in dramatic reductions in neurite process 
length and branchpoint number in G2019S and I2020T mutants. Furthermore, embryos that 
were electroporated with lentiviral LRRK2 shRNA had increased branchpoint number and a 
tendency towards increased process length206. In adult rodents, adeno-associated viral 
expression of the kinase domain WT or G2019S in the substantia nigra results in striatal 
abnormalities, including inclusions containing phosphorylated tau206. 
Recently a BAC transgenic mouse model expressing the human LRRK2 R1441G has been 
described216. An age-dependent levodopa-responsive motor-activity deficit was observed. 
Moreover, neuropathological analyses showed diminished dopamine release and axonal 
pathology of nigrostriatal dopaminergic projection. This model seems to successfully 
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recapitulate the phenotypical, neurochemical and histopathological features of the human 
disease. 
 
Considering all these data, it seems that it is still too early to draw any conclusion on the 
physiologic role of LRRK2. The observation of retarded axon outgrowth in primary 
neurons of transgenic G2019S mice and the clinical and pathological features of the 
LRRK2-R1441G transgenic mice seems to represent an exquisite model to study the 
disease, but how and why the mutated LRRK2 would affect only dopaminergic neurons 
and which interactors play a role in this mechanism remains to be explored. 
Chapter 1 
 49 
References 
 
 
1. Fahn, S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991, 1-14 
(2003). 
2. Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 
(2003). 
3. Cookson, M.R. The biochemistry of Parkinson's disease. Annu Rev Biochem 74, 29-52 (2005). 
4. Polymeropoulos, M.H. et al. Mutation in the alpha-synuclein gene identified in families with 
Parkinson's disease. Science 276, 2045-2047 (1997). 
5. Singleton, A.B. et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 
(2003). 
6. Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked 
Parkinson's disease. Neuron 44, 595-600 (2004). 
7. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic 
pathology. Neuron 44, 601-607 (2004). 
8. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. 
Nature 392, 605-608 (1998). 
9. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset 
parkinsonism. Science 299, 256-259 (2003). 
10. Valente, E.M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. 
Science 304, 1158-1160 (2004). 
11. Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, 
encoding a lysosomal type 5 P-type ATPase. Nat Genet 38, 1184-1191 (2006). 
12. Paisan-Ruiz, C. et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Annals of 
neurology 65, 19-23 (2009). 
13. Di Fonzo, A. et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-
pyramidal syndrome. Neurology 72, 240-245 (2009). 
14. Shojaee, S. et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 
500 K SNP arrays. American journal of human genetics 82, 1375-1384 (2008). 
15. Le, W.D. et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 33, 85-89 
(2003). 
16. Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452 (1998). 
17. Strauss, K.M. et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's 
disease. Hum Mol Genet 14, 2099-2111 (2005). 
18. Lautier, C. et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial 
Parkinson disease. American journal of human genetics 82, 822-833 (2008). 
19. Gasser, T. et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 
18, 262-265 (1998). 
20. Li, Y.J. et al. Age at onset in two common neurodegenerative diseases is genetically controlled. 
American journal of human genetics 70, 985-993 (2002). 
21. Pankratz, N. et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample 
without parkin mutations. American journal of human genetics 71, 124-135 (2002). 
22. Elbaz, A. et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in 
Parkinson's disease: a large-scale international study. Lancet Neurol 5, 917-923 (2006). 
23. Fung, H.C. et al. Genome-wide genotyping in Parkinson's disease and neurologically normal 
controls: first stage analysis and public release of data. Lancet Neurol 5, 911-916 (2006). 
24. Bertoli-Avella, A.M. et al. Evidence for novel loci for late-onset Parkinson's disease in a genetic 
isolate from the Netherlands. Human genetics 119, 51-60 (2006). 
25. Foltynie, T. et al. A genome wide linkage disequilibrium screen in Parkinson's disease. J Neurol 
252, 597-602 (2005). 
26. Gonzalez-Perez, A. et al. Whole-genome conditional two-locus analysis identifies novel candidate 
genes for late-onset Parkinson's disease. Neurogenetics 10, 173-181 (2009). 
27. Pankratz, N. et al. Genomewide association study for susceptibility genes contributing to familial 
Parkinson disease. Human genetics 124, 593-605 (2009). 
Introduction 
 50 
28. Sutherland, G.T. et al. Do polymorphisms in the familial Parkinsonism genes contribute to risk for 
sporadic Parkinson's disease? Mov Disord 24, 833-838 (2009). 
29. Skipper, L. et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. 
American journal of human genetics 75, 669-677 (2004). 
30. Tobin, J.E. et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: 
the GenePD Study. Neurology 71, 28-34 (2008). 
31. Zabetian, C.P. et al. Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's 
disease. Annals of neurology 62, 137-144 (2007). 
32. Funayama, M. et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-
q13.1. Annals of neurology 51, 296-301 (2002). 
33. Hasegawa, K. et al. Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred 
with variable clinicopathologic outcomes. Parkinsonism Relat Disord (2008). 
34. Scott, W.K. et al. Fine mapping of the chromosome 12 late-onset Alzheimer disease locus: potential 
genetic and phenotypic heterogeneity. American journal of human genetics 66, 922-932 (2000). 
35. Zimprich, A. et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage 
and further delineation of the disease-containing interval. American journal of human genetics 74, 
11-19 (2004). 
36. Paisan-Ruiz, C. et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque 
families. Annals of neurology 57, 365-372 (2005). 
37. Wszolek, Z.K. et al. Autosomal dominant parkinsonism associated with variable synuclein and tau 
pathology. Neurology 62, 1619-1622 (2004). 
38. Di Fonzo, A. et al. A frequent LRRK2 gene mutation associated with autosomal dominant 
Parkinson's disease. Lancet 365, 412-415 (2005). 
39. Gilks, W.P. et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365, 415-
416 (2005). 
40. Nichols, W.C. et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's 
disease. Lancet 365, 410-412 (2005). 
41. Kachergus, J. et al. Identification of a novel LRRK2 mutation linked to autosomal dominant 
parkinsonism: evidence of a common founder across European populations. American journal of 
human genetics 76, 672-680 (2005). 
42. Funayama, M. et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 
family. Annals of neurology 57, 918-921 (2005). 
43. Lesage, S. et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J 
Med 354, 422-423 (2006). 
44. Ozelius, L.J. et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J 
Med 354, 424-425 (2006). 
45. Ishihara, L. et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North 
American Caucasian Parkinson's disease families. Mov Disord 22, 55-61 (2007). 
46. Lesage, S. et al. G2019S LRRK2 mutation in French and North African families with Parkinson's 
disease. Annals of neurology 58, 784-787 (2005). 
47. Tomiyama, H. et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease 
patients from 18 countries. Mov Disord 21, 1102-1108 (2006). 
48. Clark, L.N. et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. 
Neurology 67, 1786-1791 (2006). 
49. Deng, H. et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol 
Sci 251, 102-106 (2006). 
50. Djaldetti, R. et al. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in 
Israel. J Neural Transm 115, 1279-1284 (2008). 
51. Change, N., Mercier, G. & Lucotte, G. Genetic screening of the G2019S mutation of the LRRK2 
gene in Southwest European, North African, and Sephardic Jewish subjects. Genet Test 12, 333-339 
(2008). 
52. Saunders-Pullman, R. et al. Increased frequency of the LRRK2 G2019S mutation in an elderly 
Ashkenazi Jewish population is not associated with dementia. Neurosci Lett 402, 92-96 (2006). 
53. Pirkevi, C. et al. A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype. 
Neurogenetics (2009). 
Chapter 1 
 51 
54. Okubadejo, N. et al. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations 
in LRRK2, PRKN and ATXN3. PLoS ONE 3, e3421 (2008). 
55. Shojaee, S. et al. A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in 
Iranian Parkinson's disease patients. Mov Disord (2009). 
56. Bras, J.M. et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a 
Portuguese cohort. Mov Disord 20, 1653-1655 (2005). 
57. Ferreira, J.J. et al. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease 
in Portugal. Mov Disord 22, 1194-1201 (2007). 
58. Gaig, C. et al. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical 
features, and incomplete penetrance. Arch Neurol 63, 377-382 (2006). 
59. Gonzalez-Fernandez, M.C. et al. Lrrk2-associated parkinsonism is a major cause of disease in 
Northern Spain. Parkinsonism Relat Disord 13, 509-515 (2007). 
60. Infante, J. et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset 
Parkinson's disease. Neurosci Lett 395, 224-226 (2006). 
61. Mata, I.F. et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 
13, 391-394 (2006). 
62. Gorostidi, A., Ruiz-Martinez, J., Lopez de Munain, A., Alzualde, A. & Marti Masso, J.F. LRRK2 
G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque 
Country, but relative prevalence is determined by ethnicity. Neurogenetics (2008). 
63. Civitelli, D. et al. LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's 
disease. Clin Genet 71, 367-370 (2007). 
64. De Rosa, A. et al. Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease 
patients from Southern Italy. Parkinsonism Relat Disord 15, 242-244 (2009). 
65. Di Fonzo, A. et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's 
disease. Eur J Hum Genet 14, 322-331 (2006). 
66. Goldwurm, S. et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late 
onset Parkinson's disease and originates from a common ancestor. J Med Genet 42, e65 (2005). 
67. Marongiu, R. et al. Frequency and phenotypes of LRRK2 G2019S mutation in Italian patients with 
Parkinson's disease. Mov Disord 21, 1232-1235 (2006). 
68. Lesage, S. et al. Molecular analyses of the LRRK2 gene in European and North-African autosomal 
dominant Parkinson's disease. J Med Genet (2009). 
69. Lesage, S. et al. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch Neurol 
64, 425-430 (2007). 
70. Lesage, S. et al. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease. 
Neurodegener Dis 4, 195-198 (2007). 
71. Funalot, B., Nichols, W.C., Perez-Tur, J., Mercier, G. & Lucotte, G. Genetic screening for two 
LRRK2 mutations in French patients with idiopathic Parkinson's disease. Genet Test 10, 290-293 
(2006). 
72. Cossu, G. et al. LRRK2 mutations and Parkinson's disease in Sardinia--A Mediterranean genetic 
isolate. Parkinsonism Relat Disord 13, 17-21 (2007). 
73. Floris, G. et al. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: 
Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. 
Parkinsonism Relat Disord (2008). 
74. Kalinderi, K., Fidani, L., Bostantjopoulou, S., Katsarou, Z. & Kotsis, A. The G2019S LRRK2 
mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. Eur J Neurol 14, 
1088-1090 (2007). 
75. Papapetropoulos, S. et al. Is the G2019S LRRK2 mutation common in all southern European 
populations? J Clin Neurosci 15, 1027-1030 (2008). 
76. Papapetropoulos, S., Argyriou, A.A., Mitsi, G. & Chroni, E. Re: The G2019S LRRK2 mutation is 
uncommon amongst Greek patients with familial Parkinson's disease. Eur J Neurol 14, e6 (2007). 
77. Spanaki, C., Latsoudis, H. & Plaitakis, A. LRRK2 mutations on Crete: R1441H associated with PD 
evolving to PSP. Neurology 67, 1518-1519 (2006). 
78. Khan, N.L. et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial 
Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 
128, 2786-2796 (2005). 
Introduction 
 52 
79. Williams-Gray, C.H. et al. Prevalence of the LRRK2 G2019S mutation in a UK community based 
idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry 77, 665-667 (2006). 
80. Mata, I.F. et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171-177 
(2005). 
81. Toft, M., Haugarvoll, K., Ross, O.A., Farrer, M.J. & Aasly, J.O. LRRK2 and Parkinson's disease in 
Norway. Acta Neurol Scand Suppl 187, 72-75 (2007). 
82. Carmine Belin, A. et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson 
cohort and a healthy nonagenarian. Mov Disord 21, 1731-1734 (2006). 
83. Hedrich, K. et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson's disease. Mov 
Disord 21, 1506-1510 (2006). 
84. Moller, J.C. et al. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German 
patients with Parkinson's disease. Eur J Neurol 15, 743-745 (2008). 
85. Berg, D. et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic 
Parkinson's disease*. Brain 128, 3000-3011 (2005). 
86. Nuytemans, K. et al. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian 
Parkinson's disease patients. Eur J Hum Genet 16, 471-479 (2008). 
87. Macedo, M.G. et al. Genotypic and phenotypic characteristics of Dutch patients with early onset 
Parkinson's disease. Mov Disord 24, 196-203 (2009). 
88. Haubenberger, D. et al. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's 
disease. Mov Disord 22, 1640-1643 (2007). 
89. Schlitter, A.M., Woitalla, D., Mueller, T., Epplen, J.T. & Dekomien, G. The LRRK2 gene in 
Parkinson's disease: mutation screening in patients from Germany. J Neurol Neurosurg Psychiatry 
77, 891-892 (2006). 
90. Bialecka, M. et al. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. 
Neurosci Lett 390, 1-3 (2005). 
91. Illarioshkin, S.N. et al. A common leucine-rich repeat kinase 2 gene mutation in familial and 
sporadic Parkinson's disease in Russia. Eur J Neurol 14, 413-417 (2007). 
92. Pchelina, S.N. et al. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: 
identification of a novel LRRK2 variant. Eur J Neurol 15, 692-696 (2008). 
93. Pchelina, S.N. et al. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in 
Russia. Mov Disord 21, 2234-2236 (2006). 
94. Shadrina, M.I. et al. [A PARK8 form of Parkinson's disease: a mutational analysis of the LRRK2 
gene in Russian population]. Zh Nevrol Psikhiatr Im S S Korsakova 107, 46-50 (2007). 
95. Chen-Plotkin, A.S. et al. Corticobasal syndrome and primary progressive aphasia as manifestations 
of LRRK2 gene mutations. Neurology 70, 521-527 (2008). 
96. Johnson, J. et al. Comprehensive screening of a North American Parkinson's disease cohort for 
LRRK2 mutation. Neurodegener Dis 4, 386-391 (2007). 
97. Kay, D.M. et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. 
movement disorder clinics. Mov Disord 21, 519-523 (2006). 
98. Paisan-Ruiz, C., Nath, P., Washecka, N., Gibbs, J.R. & Singleton, A.B. Comprehensive analysis of 
LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum 
Mutat 29, 485-490 (2008). 
99. Papapetropoulos, S. et al. Clinical heterogeneity of the LRRK2 G2019S mutation. Arch Neurol 63, 
1242-1246 (2006). 
100. Patra, B. et al. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's 
disease. Parkinsonism Relat Disord 15, 175-180 (2009). 
101. Scholz, S. et al. LRRK2 mutations in a clinic-based cohort of Parkinson's disease. Eur J Neurol 13, 
1298-1301 (2006). 
102. Dupre, N. et al. LRRK2 is not a significant cause of Parkinson's disease in French-Canadians. Can J 
Neurol Sci 34, 333-335 (2007). 
103. Grimes, D.A., Racacho, L., Han, F., Panisset, M. & Bulman, D.E. LRRK2 screening in a Canadian 
Parkinson's disease cohort. Can J Neurol Sci 34, 336-338 (2007). 
104. Mata, I.F. et al. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. 
Parkinsonism Relat Disord (2008). 
105. Perez-Pastene, C. et al. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease. 
Neurosci Lett 422, 193-197 (2007). 
Chapter 1 
 53 
106. Camargos, S.T. et al. Familial Parkinsonism and early onset Parkinson's disease in a Brazilian 
movement disorders clinic: Phenotypic characterization and frequency of SNCA, PRKN, PINK1, 
and LRRK2 mutations. Mov Disord (2009). 
107. Munhoz, R.P. et al. The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: 
phenotype in monozygotic twins. Mov Disord 23, 290-294 (2008). 
108. Pimentel, M.M. et al. A study of LRRK2 mutations and Parkinson's disease in Brazil. Neurosci Lett 
433, 17-21 (2008). 
109. Fung, H.C. et al. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic 
Parkinson's disease. Mov Disord 21, 880-881 (2006). 
110. Lin, C.H. et al. LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, 
PET, and functional studies. J Biomed Sci 15, 661-667 (2008). 
111. Lu, C.S. et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients 
with sporadic Parkinson's disease. Parkinsonism Relat Disord 11, 521-522 (2005). 
112. Tan, E.K. et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's 
disease patients. Neurosci Lett 384, 327-329 (2005). 
113. Cho, J.W. et al. The G2019S LRRK2 mutation is rare in Korean patients with Parkinson's disease. 
Can J Neurol Sci 34, 53-55 (2007). 
114. Choi, J.M. et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. 
Neurogenetics 9, 263-269 (2008). 
115. Punia, S. et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's 
disease patients. Neurosci Lett 409, 83-88 (2006). 
116. Zabetian, C.P. et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients 
with Parkinson disease. Neurology 67, 697-699 (2006). 
117. Huang, Y. et al. Prevalence and clinical features of common LRRK2 mutations in Australians with 
Parkinson's disease. Mov Disord 22, 982-989 (2007). 
118. Mellick, G.D. et al. Screening PARK genes for mutations in early-onset Parkinson's disease patients 
from Queensland, Australia. Parkinsonism Relat Disord 15, 105-109 (2009). 
119. Hernandez, D.G. et al. Clinical and positron emission tomography of Parkinson's disease caused by 
LRRK2. Annals of neurology 57, 453-456 (2005). 
120. Zabetian, C.P. et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe 
and the Middle East: evidence of two distinct founding events beginning two millennia ago. 
American journal of human genetics 79, 752-758 (2006). 
121. Lesage, S. et al. LRRK2 haplotype analyses in European and North African families with Parkinson 
disease: a common founder for the G2019S mutation dating from the 13th century. American journal 
of human genetics 77, 330-332 (2005). 
122. Watterson, G.A. & Guess, H.A. Is the most frequent allele the oldest? Theor Popul Biol 11, 141-160 
(1977). 
123. Warren, L. et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle 
Eastern families with Parkinson's disease. Parkinsonism Relat Disord 14, 77-80 (2008). 
124. Bar-Shira, A., Hutter, C.M., Giladi, N., Zabetian, C.P. & Orr-Urtreger, A. Ashkenazi Parkinson's 
disease patients with the LRRK2 G2019S mutation share a common founder dating from the second 
to fifth centuries. Neurogenetics (2009). 
125. Benamer, H.T. The ancestry of LRRK2 Gly2019Ser parkinsonism. Lancet Neurol 7, 769-770; author 
reply 770-761 (2008). 
126. Goldwurm, S. et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in 
Parkinson disease. Neurology 68, 1141-1143 (2007). 
127. Healy, D.G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated 
Parkinson's disease: a case-control study. Lancet Neurol 7, 583-590 (2008). 
128. Latourelle, J.C. et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial 
Parkinson's disease: the GenePD study. BMC Med 6, 32 (2008). 
129. Ishihara, L. et al. Clinical features of Parkinson disease patients with homozygous leucine-rich 
repeat kinase 2 G2019S mutations. Arch Neurol 63, 1250-1254 (2006). 
130. Marras, C. et al. LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-
phenotype correlation. Neurobiol Aging (2008). 
131. Dachsel, J.C. et al. Digenic parkinsonism: investigation of the synergistic effects of PRKN and 
LRRK2. Neurosci Lett 410, 80-84 (2006). 
Introduction 
 54 
132. Paisan-Ruiz, C. et al. LRRK2 gene in Parkinson disease: mutation analysis and case control 
association study. Neurology 65, 696-700 (2005). 
133. Golub, Y. et al. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. 
Parkinsonism Relat Disord (2008). 
134. Zabetian, C.P. et al. A clinic-based study of the LRRK2 gene in Parkinson disease yields new 
mutations. Neurology 65, 741-744 (2005). 
135. Tan, E.K. et al. Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late-onset 
Parkinson's disease. Mov Disord 21, 997-1001 (2006). 
136. Haugarvoll, K. et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. 
Neurology 70, 1456-1460 (2008). 
137. Simon-Sanchez, J. et al. Parkinson's disease due to the R1441G mutation in Dardarin: a founder 
effect in the Basques. Mov Disord 21, 1954-1959 (2006). 
138. Mata, I.F. et al. LRRK2 R1441G in Spanish patients with Parkinson's disease. Neurosci Lett 382, 
309-311 (2005). 
139. Mata, I.F. et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in 
the seventh century in Northern Spain. Neurogenetics (2009). 
140. Gomez-Esteban, J.C. et al. Outcome of bilateral deep brain subthalamic stimulation in patients 
carrying the R1441G mutation in the LRRK2 dardarin gene. Neurosurgery 62, 857-862; discussion 
862-853 (2008). 
141. Santpere, G. & Ferrer, I. LRRK2 and neurodegeneration. Acta Neuropathol 117, 227-246 (2009). 
142. Ross, O.A. et al. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism 
Relat Disord (2008). 
143. Gaig, C. et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series 
of parkinsonian syndromes and frontotemporal lobar degeneration. J Neurol Sci 270, 94-98 (2008). 
144. Farrer, M. et al. LRRK2 mutations in Parkinson disease. Neurology 65, 738-740 (2005). 
145. Skipper, L. et al. Analysis of LRRK2 functional domains in nondominant Parkinson disease. 
Neurology 65, 1319-1321 (2005). 
146. Zabetian, C.P. et al. LRRK2 mutations and risk variants in Japanese patients with Parkinson's 
disease. Mov Disord (2009). 
147. Nichols, W.C. et al. LRRK2 mutation analysis in Parkinson disease families with evidence of 
linkage to PARK8. Neurology 69, 1737-1744 (2007). 
148. Xiromerisiou, G. et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal 
dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 14, 7-11 
(2007). 
149. Di Fonzo, A. et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with 
Parkinson's disease risk in Taiwan. Neurogenetics 7, 133-138 (2006). 
150. Clarimon, J. et al. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation 
screening. Mov Disord 23, 518-523 (2008). 
151. Deng, H. et al. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's 
disease. Neurosci Lett 419, 104-107 (2007). 
152. Tan, E.K., Lim, H.Q., Yuen, Y. & Zhao, Y. Pathogenicity of LRRK2 P755L variant in Parkinson's 
disease. Mov Disord 23, 734-736 (2008). 
153. Tomiyama, H. et al. LRRK2 P755L variant in sporadic Parkinson's disease. J Hum Genet 53, 1012-
1015 (2008). 
154. Nichols, W.C. et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. 
Mov Disord 22, 254-257 (2007). 
155. Toft, M. et al. Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord 
22, 389-392 (2007). 
156. Gasser, T. Mendelian forms of Parkinson's disease. Biochim Biophys Acta (2009). 
157. Adams, J.R. et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and 
evidence for presymptomatic compensation. Brain 128, 2777-2785 (2005). 
158. Giasson, B.I. et al. Biochemical and pathological characterization of Lrrk2. Annals of neurology 59, 
315-322 (2006). 
159. Giordana, M.T. et al. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val 
mutation. Mov Disord 22, 275-278 (2007). 
160. Ross, O.A. et al. Lrrk2 and Lewy body disease. Annals of neurology 59, 388-393 (2006). 
Chapter 1 
 55 
161. Hasegawa, K. et al. Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred 
with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15, 300-306 (2009). 
162. Santos-Reboucas, C.B. et al. Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's 
disease in a Brazilian male with the LRRK2 p.G2019S mutation. Genet Test 12, 471-473 (2008). 
163. Gaig, C. et al. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J Neurol 
Neurosurg Psychiatry 78, 626-628 (2007). 
164. Rajput, A. et al. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67, 1506-1508 
(2006). 
165. Zabetian, C.P. et al. Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. Arch Neurol 
63, 156-157 (2006). 
166. Toft, M. et al. LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 126, 
1201-1205 (2005). 
167. Tedde, A. et al. No association between the LRRK2 G2019S mutation and Alzheimer's disease in 
Italy. Cell Mol Neurobiol 27, 877-881 (2007). 
168. Lee, E., Hui, S., Ho, G., Tan, E.K. & Chen, C.P. LRRK2 G2019S and I2020T mutations are not 
common in Alzheimer's disease and vascular dementia. Am J Med Genet B Neuropsychiatr Genet 
141B, 549-550 (2006). 
169. Ozelius, L.J. et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with 
multiple system atrophy. Mov Disord 22, 546-549 (2007). 
170. Hernandez, D. et al. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but 
not other neurodegenerative diseases. Neurosci Lett 389, 137-139 (2005). 
171. Madzar, D., Schulte, C. & Gasser, T. Screening for LRRK2 R1441 mutations in a cohort of PSP 
patients from Germany. Eur J Neurol (2009). 
172. Deng, H., Le, W., Davidson, A.L., Xie, W. & Jankovic, J. The LRRK2 I2012T, G2019S and I2020T 
mutations are not common in patients with essential tremor. Neurosci Lett 407, 97-100 (2006). 
173. Biskup, S. et al. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. 
Annals of neurology 58, 905-908 (2005). 
174. Skipper, L. et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals 
evidence for association with sporadic Parkinson's disease. Hum Mol Genet 14, 3549-3556 (2005). 
175. Chan, D.K. et al. LRRK2 Gly2385Arg mutation and clinical features in a Chinese population with 
early-onset Parkinson's disease compared to late-onset patients. J Neural Transm 115, 1275-1277 
(2008). 
176. Funayama, M. et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson 
disease in Asian population. Neuroreport 18, 273-275 (2007). 
177. Farrer, M.J. et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. 
Parkinsonism Relat Disord 13, 89-92 (2007). 
178. Li, C. et al. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with 
Parkinson's disease. Mov Disord 22, 2439-2443 (2007). 
179. Tan, E.K. et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and 
functional evidence. Human genetics 120, 857-863 (2007). 
180. Tan, E.K. et al. LRRK2 G2385R modulates age at onset in Parkinson's disease: A multi-center 
pooled analysis. Am J Med Genet B Neuropsychiatr Genet (2009). 
181. Ross, O.A. et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Annals of 
neurology 64, 88-92 (2008). 
182. Tan, E.K. et al. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Human 
genetics 124, 287-288 (2008). 
183. Lu, C.S. et al. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese 
population. Neurogenetics 9, 271-276 (2008). 
184. Tan, E.K. et al. Lrrk2 R1628P in non-Chinese Asian races. Annals of neurology 64, 472-473 (2008). 
185. Bosgraaf, L. & Van Haastert, P.J. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys 
Acta 1643, 5-10 (2003). 
186. Marin, I. Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 67, 41-50 (2008). 
187. Westerlund, M. et al. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in 
the brain and other rodent and human organs: Implications for Parkinson's disease. Neuroscience 
152, 429-436 (2008). 
Introduction 
 56 
188. Gandhi, P.N., Chen, S.G. & Wilson-Delfosse, A.L. Leucine-rich repeat kinase 2 (LRRK2): A key 
player in the pathogenesis of Parkinson's disease. J Neurosci Res 87, 1283-1295 (2008). 
189. Greggio, E. et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. 
Neurobiol Dis 23, 329-341 (2006). 
190. Miklossy, J. et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration 
caused by the N279K tau mutation. Acta Neuropathol 114, 243-254 (2007). 
191. Perry, G. et al. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, 
but not tau-containing deposits in tauopathies. Neurodegener Dis 5, 222-224 (2008). 
192. Zhu, X., Siedlak, S.L., Smith, M.A., Perry, G. & Chen, S.G. LRRK2 protein is a component of Lewy 
bodies. Annals of neurology 60, 617-618; author reply 618-619 (2006). 
193. Alegre-Abarrategui, J., Ansorge, O., Esiri, M. & Wade-Martins, R. LRRK2 is a component of 
granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl 
Neurobiol 34, 272-283 (2008). 
194. Miklossy, J. et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. 
J Neuropathol Exp Neurol 65, 953-963 (2006). 
195. Deng, J. et al. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich 
repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105, 1499-1504 (2008). 
196. Lewis, P.A. et al. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res 
Commun 357, 668-671 (2007). 
197. Li, X. et al. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered 
in familial Parkinson's disease R1441C/G mutants. J Neurochem 103, 238-247 (2007). 
198. Smith, W.W. et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature 
neuroscience 9, 1231-1233 (2006). 
199. West, A.B. et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding 
and kinase activities to neuronal toxicity. Hum Mol Genet 16, 223-232 (2007). 
200. Ito, G. et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene 
product for familial Parkinson's disease. Biochemistry 46, 1380-1388 (2007). 
201. West, A.B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment 
kinase activity. Proc Natl Acad Sci U S A 102, 16842-16847 (2005). 
202. Luzon-Toro, B., Rubio de la Torre, E., Delgado, A., Perez-Tur, J. & Hilfiker, S. Mechanistic insight 
into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol 
Genet 16, 2031-2039 (2007). 
203. Nolen, B., Taylor, S. & Ghosh, G. Regulation of protein kinases; controlling activity through 
activation segment conformation. Mol Cell 15, 661-675 (2004). 
204. Jaleel, M. et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how 
Parkinson's disease mutants affect kinase activity. Biochem J 405, 307-317 (2007). 
205. Gloeckner, C.J. et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with 
increased kinase activity. Hum Mol Genet 15, 223-232 (2006). 
206. MacLeod, D. et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. 
Neuron 52, 587-593 (2006). 
207. Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K. & Hisamoto, N. LRK-1, a C. elegans 
PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 17, 592-598 
(2007). 
208. Samann, J. et al. Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response 
and neurite outgrowth. J Biol Chem (2009). 
209. Wolozin, B., Saha, S., Guillily, M., Ferree, A. & Riley, M. Investigating convergent actions of genes 
linked to familial Parkinson's disease. Neurodegener Dis 5, 182-185 (2008). 
210. Lee, S.B., Kim, W., Lee, S. & Chung, J. Loss of LRRK2/PARK8 induces degeneration of 
dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358, 534-539 (2007). 
211. Wang, D. et al. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of 
dopaminergic neurons. Mol Neurodegener 3, 3 (2008). 
212. Liu, Z. et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105, 
2693-2698 (2008). 
213. Biskup, S. et al. Localization of LRRK2 to membranous and vesicular structures in mammalian 
brain. Annals of neurology 60, 557-569 (2006). 
Chapter 1 
 57 
214. Biskup, S. et al. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC 
Neurosci 8, 102 (2007). 
215. Wang, L. et al. The chaperone activity of heat shock protein 90 is critical for maintaining the 
stability of leucine-rich repeat kinase 2. J Neurosci 28, 3384-3391 (2008). 
216. Li, Y. et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of 
Parkinson's disease. Nature neuroscience 12, 826-828 (2009). 
Chapter 2 
 58 
Chapter 2 
 59 
Chapter 2 - A frequent LRRK2 gene 
mutation associated with autosomal 
dominant Parkinson’s disease 
 
Alessio Di Fonzo, Christan F Rohé, Joaquim Ferreira, Hsin F Chien, Laura Vacca, Fabrizio Stocchi, Leonor 
Guedes, Edito Fabrizio, Mario Manfredi, Nicola Vanacore, Stefano Goldwurm, Guido Breedveld, Cristina 
Sampaio, Giuseppe Meco, Egberto Barbosa, Ben A Oostra, Vincenzo Bonifati, and the Italian Parkinson 
Genetics Network 
 
Lancet. 2005 Jan 29-Feb 4;365(9457):412-5 
 
Chapter 2 
 60 
Chapter 2 
 61 
 
Chapter 2 
 62 
Chapter 2 
 63 
 
Chapter 2 
 64 
 
Chapter 3 
 65 
Chapter 3 - The G6055A (G2019S) 
mutation in LRRK2 is frequent in both 
early and late onset Parkinson’s disease 
and originates from a common ancestor 
 
S Goldwurm, A Di Fonzo, E J Simons, C F Rohé, M Zini, M Canesi, S Tesei, A Zecchinelli, A Antonini, C 
Mariani, N Meucci, G Sacilotto, F Sironi, G Salani, J Ferreira, H F Chien, E Fabrizio, N Vanacore, A Dalla 
Libera, F Stocchi, C Diroma, P Lamberti, C Sampaio, G Meco, E Barbosa, A M Bertoli-Avella, G J 
Breedveld, B A Oostra, G Pezzoli and V Bonifati 
 
J. Med. Genet. 2005;42;e65 doi:10.1136/jmg.2005.035568 
 
 
Chapter 3 
 66 
Chapter 3 
 67 
Chapter 3 
 68 
Chapter 3 
 69 
Chapter 3 
 70 
Chapter 3 
 71 
Chapter 3 
 72 
Chapter 3 
 73 
Chapter 3 
 74 
 
Chapter 4 
 75 
Chapter 4 - Comprehensive analysis of the 
LRRK2 gene in sixty families with 
Parkinson’s disease 
 
Alessio Di Fonzo, Cristina Tassorelli, Michele De Mari, Hsin F. Chien, Joaquim Ferreira, Christan F. Rohe´, 
Giulio Riboldazzi, Angelo Antonini, Gianni Albani, Alessandro Mauro, Roberto Marconi, Giovanni 
Abbruzzese, Leonardo Lopiano, Emiliana Fincati, Marco Guidi, Paolo Marini, Fabrizio Stocchi, Marco 
Onofrj, Vincenzo Toni, Michele Tinazzi, Giovanni Fabbrini1, Paolo Lamberti, Nicola Vanacore, Giuseppe 
Meco, Petra Leitner, Ryan J. Uitti, Zbigniew K. Wszolek, Thomas Gasser, Erik J. Simons, Guido J. 
Breedveld, Stefano Goldwurm, Gianni Pezzoli, Cristina Sampaio, Egberto Barbosa, Emilia Martignoni, Ben 
A. Oostra, Vincenzo Bonifati, and The Italian Parkinson Genetics Network 
 
Eur J Hum Genet. 2006 Mar;14(3):322-31. 
Chapter 4 
 76 
Chapter 4 
 77 
Chapter 4 
 78 
Chapter 4 
 79 
Chapter 4 
 80 
Chapter 4 
 81 
Chapter 4 
 82 
Chapter 4 
 83 
Chapter 4 
 84 
Chapter 4 
 85 
 
Chapter 4 
 86 
Chapter 5 
 87 
Chapter 5 - A common missense variant in 
the LRRK2 gene, Gly2385Arg, associated 
with Parkinson’s disease risk in Taiwan 
 
Alessio Di Fonzo, Yah-Huei Wu-Chou, Chin-Song Lu, Marina van Doeselaar, Erik J. Simons, Christan F. 
Rohé, Hsiu-Chen Chang, Rou-Shayn Chen, Yi-Hsin Weng, Nicola Vanacore, Guido J. Breedveld, Ben A. 
Oostra, Vincenzo Bonifati 
 
Neurogenetics. 2006 Jul;7(3):133-8. Epub 2006 Apr 22. 
Chapter 5 
 88 
Chapter 5 
 89 
Chapter 5 
 90 
Chapter 5 
 91 
 
Chapter 5 
 92 
 
Chapter 5 
 93 
Chapter 5 
 94 
 
Chapter 6 
 95 
Chapter 6 - LRRK2 mutations and 
Parkinson’s disease in Sardinia - A 
Mediterranean genetic isolate 
 
Giovanni Cossu, Marina van Doeselaar, Marcello Deriu, Maurizio Melis, Andrea Molari, Alessio Di Fonzo, 
Ben A. Oostra, Vincenzo Bonifati 
 
Parkinsonism Relat Disord. 2007 Feb;13(1):17-21. Epub 2006 Oct 24. 
Chapter 6 
 96 
Chapter 6 
 97 
Chapter 6 
 98 
Chapter 6 
 99 
 
Chapter 6 
 100 
 
Chapter 6 
 101 
 
Chapter 6 
 102 
Chapter 7 
 103 
Chapter 7 - High Prevalence of LRRK2 
Mutations in Familial and Sporadic 
Parkinson’s Disease in Portugal 
 
Joaquim J. Ferreira,  Leonor Correia Guedes,  Mario Miguel Rosa,  Miguel Coelho,  Marina van Doeselaar, 
Dorothea Schweiger,  Alessio Di Fonzo,  Ben A. Oostra,  Cristina Sampaio,  and Vincenzo Bonifati 
 
Mov Disord. 2007 Jun 15;22(8):1194-201. 
Chapter 7 
 104 
Chapter 7 
 105 
 
Chapter 7 
 106 
Chapter 7 
 107 
Chapter 7 
 108 
Chapter 7 
 109 
Chapter 7 
 110 
Chapter 7 
 111 
 
Chapter 7 
 112 
Chapter 8 
 113 
Chapter 8 - Neuropathology of 
Parkinson’s Disease Associated With the 
LRRK2 Ile1371Val Mutation 
 
Maria Teresa Giordana, Carla D’Agostino, Giovanni Albani, Alessandro Mauro, Alessio Di Fonzo,  Angelo 
Antonini, and Vincenzo Bonifati 
 
Mov Disord. 2007 Jan 15;22(2):275-8. 
Chapter 8 
 114 
Chapter 8 
 115 
Chapter 8 
 116 
Chapter 8 
 117 
Chapter 8 
 118 
 
Chapter 9 
 119 
Chapter 9 - The LRRK2 Arg1628Pro 
variant is a risk factor for Parkinson’s 
disease in the Chinese population 
 
Chin-Song Lu, Yah-Huei Wu-Chou, Marina van Doeselaar, Erik J. Simons, Hsiu-Chen Chang, Guido J. 
Breedveld, Alessio Di Fonzo, Rou-Shayn Chen, Yi-Hsin Weng, Szu-Chia La , Ben A. Oostra, Vincenzo 
Bonifati  
 
Neurogenetics. 2008 Oct;9(4):271-6. Epub 2008 Aug 21. 
Chapter 9 
 120 
Chapter 9 
 121 
Chapter 9 
 122 
Chapter 9 
 123 
Chapter 9 
 124 
Chapter 9 
 125 
 
Chapter 9 
 126 
 
Chapter 10 
 127 
Chapter 10 - General Discussion 
Discussion 
 128 
Chapter 10 
 129 
In the past decade significant progress has been made in the dissection of the molecular 
biology of Parkinson’s disease. An important contribution to this understanding was made 
by the discovery of genes implicated in familial forms of the disease.  
Among these genes, the role of LRRK2 is remarkable since its mutations have been 
reported, for the first time and with an unprecedented high frequency, not only in familial, 
but also in sporadic cases.  
The G2019S mutation alone accounts for up to 6% to 16% of familial PD and in 1% to 4% 
of sporadic cases in some European populations and in many more cases among Arab and 
Ashkenazy Jewish populations, representing the most frequent genetic cause of PD known 
so far1. The prevalence of this mutation is strongly population specific, since it is 
particularly frequent in North Africa, where it probably originated, and in the surrounding 
countries wherein it was spread during the centuries.  
Further studies on the whole coding region of this large gene are warranted in order to 
identify LRRK2 mutations that might be the counterpart of the G2019S in other 
populations. This is the case for the R1441G mutation, for example, which is specific of the 
Basque and Northern Spain regions2-4.   
To make this picture even more complex, the G2019S itself and other LRRK2 mutations as 
the R1441C and R1441H have been found in the context of different haplotypes, 
suggesting independent mutational events5, 6. 
The presence of different mutational hot-spots and a high polymorphic content suggest that 
the LRRK2 gene is particularly unstable and prone to mutations. Many intronic and exonic 
nucleotide changes have been reported so far in PD patients and controls. Some of them 
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represent non-pathogenic polymorphisms. However, for a consistent group of variants the 
pathogenic role has still to be elucidated.  
Another specific characteristic of LRRK2 mutations is the reduced penetrance, especially of 
the common G2019S, which has been estimated to be ~30% in some populations7-9. Such a 
low penetrance is in line with the high prevalence of this mutation among sporadic patients 
and the rare occurrence in controls (~1%), particularly among the populations with the 
highest mutation frequencies such as Arabs and Ashkenazi Jews.  
 
An important role is also played by the G2385R variant, which in Chinese increases the 
risk to develop PD of 2.5 fold10. This variant represents the first known genetic risk factor 
for the common PD form, at least in the Asian population, and so far the most frequent 
genetic determinant of PD worldwide, especially considering the large and expanding size 
of the Chinese population.  
The discovery of the frequent low-penetrance G2019S mutation and the frequent G2385R 
risk allele provide for the first time etiological links between the familial and the sporadic 
forms of PD, and has revolutionized the previous beliefs on the contribution of genetics in 
the aetiology of this frequent and complex disorder. 
However, how LRRK2 mutations result in the death of dopaminergic neurons selectively in 
the substantia nigra has yet to be elucidated. Although exciting functional results on the 
physiologic function and consequence of the pathogenic mutations have been provided so 
far, the results are still preliminary and must be still considered with caution. The major 
limitation of the current studies is the specificity of most antibodies in detecting the 
endogenous protein, especially in its physiologic context. LRRK2 is a large peptide and 
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likely exists as dimer or even larger complexes. Due to its multiple domain structure, 
LRRK2 is predicted to have multiple functions. However, biological substrates/targets of 
LRRK2 are still undiscovered; their identification will certainly help to better understand 
its normal role, the effect of the mutations and the mechanisms that lead to cell death.  
 To date, most of the functional studies proposed a gain of function effect of the pathogenic 
mutations identified in PD cases, by either increasing the kinase activity or reducing the 
intra-molecular signalling action of the GTPase  domain11-14. Interestingly, the mechanism 
whereby mutations in different LRRK2 domains cause clinical PD may be different. 
Further studies on mammalian models will facilitate our understanding on the pleomorphic 
consequences of the LRRK2 mutation in humans.  
 
The most important question remains whether the LRRK2-associated PD represents the 
same entity of the so-called “idiopathic” PD. The evidences provided by the studies 
conducted so far are in favour of this hypothesis. The clinical phenotype of LRRK2 
mutation carriers is identical to classical PD, including a broad age of disease onset. 
Neuropathological studies also revealed that LB-positive pathology is the most common 
pattern associated to pathogenic LRRK2 mutations, particularly the common G2019S 
mutation. Rarely other clinical findings, as dementia and amyotrophy, and different 
pathologies, including nigral cell loss without distinctive inclusions, or with inclusions, 
which are stained only with ubiquitin or only with tau antibodies, might be seen. However, 
those exceptions, which do not fulfil the current clinical and neuropathological diagnostic 
criteria for PD, probably recapitulate the heterogeneity of PD itself, which can be a more 
complex disease that what we thought. From the etiopathological point of view, we might 
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hypothesize that this variability is due to a cumulative effect of different gene-environment 
and/or gene–gene interactions. In this scenario, the way to classify PD as clinical and 
neuropathological entity should be reconsidered. The LRRK2 associated PD represents an 
exceptional opportunity to retrace the definition of this disorder, since it give us the 
opportunity to study patients who share the same genetic etiology.  
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SUMMARY 
 
This thesis focuses on the role of the leucine rich repeat kinase 2 (LRRK2) gene in 
Parkinson’s disease (PD). PD is the second most frequent human neurodegenerative 
disorder after Alzheimer’s disease. The etiology of PD remains unknown in most cases, but 
several genetically-determined forms have been recently identified, which are greatly 
promoting our understanding of the disease mechanisms. Mutations in the LRRK2 gene 
were initially identified through positional cloning within the PARK8 locus in families 
with autosomal dominant inheritance of PD. Subsequent studies, included some of those 
described in this thesis, have delineated LRRK2 mutations as the most frequent, known 
cause of familial and sporadic PD.  
In Chapter 1, the studies dealing with genetic and functional aspects of LRRK2 are 
reviewed. A detailed overview of the frequency of LRRK2 mutations in familial and 
sporadic PD cases from different countries is reported. In particular, the prevalence of the 
G2019S mutation, the most common genetic determinant of PD identified so far, appears to 
be strongly population specific, since it is particularly frequent in North Africa (where it 
probably originated) and in the surrounding countries, where it has spread during the 
centuries. Of note, this mutation has a low penetrance, explaining its considerable 
prevalence also among sporadic PD cases. 
Furthermore, the data concerning the LRRK2 variants reported until now are discussed in 
order to classify them as definitely pathogenic, possibly pathogenic, or as neutral variants 
(polymorphisms). An important role is played by two LRRK2 polymorphisms, G2385R 
and R1628P, since both have been consistently associated with an increased risk to develop 
PD in the Asian population. 
In most patients with LRRK2 mutations, the phenotype is very similar to, if not 
indistinguishable from the so-called “idiopathic PD”. In some cases the associated 
pathology has been shown to be pleomorphic, raising the question whether a broader 
pathological spectrum might also be associated to the classic form of the disease. The 
functional aspects of the human LRRK2 protein are also dealt with. The results of the 
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overexpression studies of the wild type and mutant protein are in line with a gain of 
function effect of the mutations identified in PD patients. However, several caveats 
regarding the experimental procedures are highlighted, suggesting that more physiological 
models to study the effects of the mutations on the function of the LRRK2 protein are 
required.  
In Chapter 2 and 4, extensive analyses of the LRRK2 gene in PD families are described. 
The sequence of the entire LRRK2 coding region led us to identify the heterozygous 
G2019S mutation in four of 61 (6·6%) unrelated families with autosomal dominant 
Parkinson’s disease. The families originated from Italy, Portugal, and Brazil, indicating the 
presence of the mutation in different populations. The heterozygous R1441C mutation was 
also identified in two Italian families. The associated phenotype was broad, including early 
and late disease onset. The mutations co-segregated with the disease status within the 
families and were absent in population-specific control subjects, strongly supporting their 
pathogenic role.  
In Chapter 3 we report a genetic screening of the recurrent LRRK2 mutations in a large 
sample of PD patients recruited from a single Italian clinical Center. Among 629 probands, 
13 (2.1%) were heterozygous carriers of the G2019S mutation. The mutation frequency 
was higher among familial (5.1%) than among sporadic probands (0.9%) (p=0.002). There 
was no difference in the frequency of the G2019S mutation in probands with early vs late 
disease onset. Among 600 probands, one heterozygous R1441C was also detected. 
Haplotype analysis in families from five countries suggested that the G2019S mutation 
originated from a single ancient founder. The G2019S mutation was associated with the 
classical Parkinson’s disease phenotype and a broad range of onset ages (34 to 73 years). 
In Chapter 5 and 9 we report the analyses of two LRRK2 variants for association with 
disease in a large sample of PD cases and ethnically matched controls of Chinese Han 
ancestry. We showed for the first time that heterozygosity for the G2385R variant was 
significantly more frequent among PD patients than controls (nominal p value=0.004, 
corrected for multiple comparisons=0.012, gender- and age-adjusted odds ratio=2.24, 95% 
C.I.: 1.29–3.88). The R1628P allele was also more frequent among patients (3.8%) than 
among controls (1.8%; p = 0.004, OR 2.13, 95% CI 1.29–3.52). Our findings suggest that 
the LRRK2 G2385R and R1628P are the first identified, functionally relevant variants, 
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which act as common risk factors for sporadic PD in the large, expanding Chinese 
population. 
In Chapter 6 and 7 we report the analyses of the LRRK2 recurrent mutations in sporadic 
and familial PD patients from Sardinia and Portugal, respectively. Among 98 Sardinian PD 
probands we detected one heterozygous G2019S carrier, indicating the presence of the 
mutation in this genetically isolated population, although with a lower frequency than in 
the Iberian, Arab, or Jewish populations. The same mutation was also found in one of 55 
Sardinian healthy controls, an 85-year-old man, later shown to have a positive family 
history of parkinsonism, supporting the concept that this mutation displays incomplete 
penetrance. Among 138 unrelated PD probands from Portugal, we identified 9 
heterozygous G2019S carriers (6.52%) and 1 heterozygous R1441H carrier (0.72%). The 
G2019S mutation was present in 4 of the 107 sporadic (3.74%) and in 5 of the 31 familial 
probands (16.1%). Mutations were not found among 101 Portuguese controls. The G2019S 
mutation was present on a single haplotype and displayed reduced penetrance. 
In Chapter 8,  we report the first neuropathologic study in an Italian PD case carrying a 
different LRRK2 mutation, I1371V, and showing typical ubiquitin- and α-synuclein–
positive brain Lewy body pathology, supporting the concept that the neurodegeneration 
associated with LRRK2 mutations might be clinically and pathologically indistinguishable 
from typical PD. 
Finally, a general discussion on the importance of the discovery of LRRK2 mutations in 
PD, especially of the low-penetrance G2019S and the risk allele G2385R, is reported in 
Chapter 10.  
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SAMENVATTING 
 
Dit proefschrift beschrijft de rol van het gen leucine rich repeat kinase 2 (LRRK2) in de 
ziekte van Parkinson. De ziekte van Parkinson is, op de ziekte van Alzheimer na, de meest 
vaak voorkomende neurodegeneratieve aandoening. De etiologie van de ziekte van 
Parkinson in veel gevallen onbekend, echter onlangs geïdentificeerde genetische varianten 
hebben het inzicht in het ontstaan van deze ziekte sterk bevorderd. In families waarin de 
ziekte van Parkinson  autosomaal dominant over erft zijn, m.b.v. positioneel kloneren, 
mutaties gevonden in het LRRK2 gen. Aanvullende studies, waarvan enkele beschreven in 
dit proefschrift, hebben aangetoond dat mutaties in het LRRK2 gen de meest frequente 
bekende oorzaak zijn van familiaire en sporadische vormen van de ziekte van Parkinson. 
In Hoofdstuk 1 wordt een overzicht gegeven van genetische en functionele studies 
betreffende het LRRK2 gen. In detail worden de frequenties van LRRK2 mutaties 
beschreven in familiaire en sporadische vormen van de ziekte van Parkinson in 
verschillende landen, in het bijzonder het voorkomen van de G2019S mutatie, tot op heden, 
de meest voorkomende genetische determinant van de ziekte van Parkinson. Deze mutatie 
blijkt zeer populatie specifiek en komt frequent voor in Noord Afrika, waar deze mutatie is 
ontstaan en van waaruit deze zich heeft verspreidt door de eeuwen heen. Hierbij dient 
vermeldt te worden dat deze mutatie laag penetrant is, hetgeen een verklaring is voor de 
grote prevalentie bij sporadische gevallen van de ziekte van Parkinson. Aanvullend wordt 
op basis van tot op heden bekende data beargumenteerd om de  verschillende LRRK2 
varianten te classificeren of als definitief pathogeen, of als mogelijk pathogeen of als 
neutrale varianten (polymorfismen). Een bijzonder rol is weggelegd voor de twee LRRK2 
varianten G2385R and R1628P, daar beide sterk geassocieerd zijn met een verhoogd risico 
voor het verkrijgen van de ziekte van Parkinson in de Aziatische populatie.  
In de meeste patiënten met LRRK2 mutaties lijkt het ziektebeeld erg op de “idiopatische 
ziekte van Parkinson”, of is er zelfs niet van te onderscheiden. In enkele gevallen is de 
geassocieerde pathologie pleomorf, de vraag oproepend of een breder pathologisch 
spectrum ook geassocieerd kan zijn met klassieke vormen van de ziekte. De functionele 
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aspecten van het humane LRRK2 eiwit worden ook behandeld. De resultaten van 
overexpressie studies van normaal en mutant eiwit liggen in lijn met het veranderende 
functie effect door de mutaties, geïdentificeerd in patiënten met de ziekte van Parkinson. 
Echter, enkele hiaten in de experimentele procedures worden besproken die aangeven, dat 
mogelijk meer fysiologische modellen nodig zijn om het effect van mutaties op de functie 
van het LRRK2 eiwit te bestuderen.  
In Hoofdstuk 2 en 4 worden uitgebreide analyses van het LRRK2 gen in Parkinson families 
beschreven. Het bepalen in patiënten van de complete volgorde van het LRRK2 coderende 
gebied heeft geleid tot de identificatie van de heterozygote G2019S mutatie in 4 van de 61 
(6.6%) ongerelateerde families met een autosomaal dominante vorm van de ziekte van 
Parkinson. Deze families zijn afkomstig uit Italië, Portugal en Brazilië, een duidelijke 
aanwijzing van de aanwezigheid van dezelfde mutatie in verschillende populaties. De 
R1441C mutatie werd in twee Italiaanse families gevonden. Het geassocieerde fenotype 
was breed, waarbij de ziekte op zowel vroege als late leeftijd is begonnen. De pathogene 
rol van deze mutaties wordt ondersteund doordat de mutaties overerven met het ziektebeeld 
in de families en niet aanwezig zijn in populatie specifieke controle individuen. 
In Hoofdstuk 3 rapporteren wij een genetische screening van voorkomende LRRK2 
mutaties in een groot aantal patiënten afkomstig van een klinisch centrum in Italie. Van de 
629 probanden bleken 13 (2.1%) heterozygoot drager van de G2019S mutatie te zijn. De 
mutatie frequentie was hoger onder probanden in PD families (5.1%) dan onder 
sporadische probanden (0.9%) (p=0.002). Er werd geen verschil gevonden in de frequentie 
van het voorkomen van de G2019S mutatie in probanden met een vroeg ontstaan van de 
ziekte vergeleken met een laat ontstaan van de ziekte. Onder 600 probanden werd ook 1 
heterozygote drager van de R1441C mutatie gedetecteerd. Haplotype analyse in families 
met de G2019S mutatie afkomstig uit vijf verschillende landen ondersteunt de suggestie dat 
de G2019S mutatie afkomstig is van een enkele voorouder. De G2019S mutatie is 
geassocieerd met het klassieke Parkinson fenotype met een breed scala van leeftijden 
waarop de ziekte ontstond (34 tot 73 jaar).  
In Hoofdstuk 5 en 9 rapporteren wij de analyse van twee LRRK2 varianten in een groot 
aantal Parkinson patiënten met etnisch gelijke gezonde controles van Han Chinese afkomst. 
Wij toonden voor het eerst aan dat heterozygositeit voor de G2385R variant significant 
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vaker voor kwam onder Parkinson patiënten dan onder gezonde controles. (nominale p 
waarde=0.004, gecorrigeerd voor veelvoudige vergelijkingen= 0.012, herkomst en leeftijd 
aangepaste odds ratio=2.24, 95% C.I.: 1.29–3.88). Het R1628P allel werd ook frequenter 
gevonden in patiënten (3.8%) dan in controles (1.8%; p = 0.004, OR 2.13, 95% CI 1.29–
3.52). Onze bevindingen suggereren dat de G2385R en R1628P varianten in LRRK2 de 
eerste geïdentificeerde, functioneel relevante varianten zijn die als risico factoren kunnen 
worden aangewezen in de grote, steeds verder uitbreidende Chinese populatie.  
In Hoofdstuk 6 en 7 beschrijven wij de analyse van voorkomende LRRK2 mutaties in 
sporadische en familiaire Parkinson patiënten uit respectievelijk Sardinië en Portugal. 
Onder de 98 Sardinische probanden detecteerden wij een enkele heterozygote G2019S 
drager, hetgeen aantoont dat deze mutatie ook aanwezig is in deze genetisch geïsoleerde 
populatie, echter met een lagere frequentie dan in de Iberische, Arabische of joodse 
populatie. Dezelfde mutatie werd ook aangetroffen in een 1 van de 55 Sardinische gezonde 
controles, een 85 jarige gezonde man, met wat later bleek een positieve familie 
geschiedenis met de ziekte van Parkinson. Deze bevinding ondersteunt het concept dat deze 
mutatie onderhevig is aan incomplete penetrantie. Onder 138 ongerelateerde probanden 
met de ziekte van Parkinson uit Portugal hebben wij 9 heterozygote G2019S dragers 
geïdentificeerd (6.52%) and 1 heterozygote R1441H drager (0.72%). De G2019S mutatie 
was aanwezig in 4 van de 107 sporadische (3.74%) en in 5 van de 31 familiaire probanden 
(16.1%). Mutaties werden niet aangetroffen onder 101 Portugese controles. De G2019S 
mutatie was ook hier aanwezig op 1 enkel haplotype en vertoonde ook  gereduceerde 
penetrantie. 
In Hoofdstuk 8 rapporteren wij de neuropathologische studie in een Italiaanse Parkinson 
patiënt, drager van een andere LRRK2 mutatie, I1371V. Deze patiënt laat een typische 
ubiquitine en α-synucleine–positieve hersen Lewy body pathologie zien. Dit ondersteunt 
het concept dat de neurodegeneratie geassocieerd met LRRK2 mutaties klinisch en 
pathologisch niet is te onderscheiden van wat wordt waargenomen bij typische Parkinson 
patiënten. 
Ten slotte wordt in Hoofdstuk 10 een algemene discussie beschreven over het belang van 
de ontdekking van LRRK2 mutaties bij de ziekte van Parkinson, in het bijzonder de laag 
penetrante G2019S mutatie en het risico allel G2385R. 
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